Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 6.3.5.4 - asparagine synthase (glutamine-hydrolysing)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Glutaminase free l-asparaginase from Vibrio cholerae: Heterologous expression, purification and biochemical characterization.
Adenocarcinoma
Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.
Chemotherapy of the transplantable adenocarcinoma (R-3327) of the Copenhagen rat.
l-asparaginase induces intrinsic mitochondrial-mediated apoptosis in human gastric adenocarcinoma cells and impedes tumor progression.
Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4.
Afibrinogenemia
[Analysis of hypofibrinogenemias found on routine coagulation screening tests and identification of heterozygous dysfibrinogenemia or fibrinogen deficiency]
Anaphylaxis
Acute life-threatening toxicity of cancer treatment.
Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism.
Circumventing the side effects of L-asparaginase.
Comparative pharmacokinetic studies of three asparaginase preparations.
Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
Isolation and screening of L-asparaginase free of glutaminase and urease from fungal sp.
Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Solid-phase enzyme modification via affinity chromatography.
Solid-State Fermentation vs Submerged Fermentation for the Production of l-Asparaginase.
Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.
Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase.
Treatment of childhood lymphocytic leukaemia with high white-cell counts.
[Clinical experiences with adrenaline as therapy and prevention of E. coli-L-asparaginase-induced anaphylaxis]
[Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia]
[Formation of specific IgG antibodies in l-asparaginase treatment. Distribution of IgG subclasses]
Anemia, Aplastic
Concurrent Epstein-Barr virus associated NK/T cell lymphoma after immunosuppressive therapy for aplastic anemia: report of a case and review of literature.
Anemia, Hemolytic
L-asparaginase effect on the erythrocyte-immunoglobulin binding in acquired hemolytic anemia.
The L-asparaginase effect on the erythrocyte survival time in patients with acquired hemolytic anemia of the IgG and IgA type.
[Letter: Attempt at dissociation of immunoglobulins from the erythrocytic surface of a patient with hemolytic anemia caused by L-asparaginase in vitro experiment (author's transl)]
Antiphospholipid Syndrome
Pediatric thromboembolism: a national survey in Japan.
Antithrombin III Deficiency
Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy.
L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state.
[L-asparaginase, antithrombin III deficiency and thromboses (author's transl)]
[Monitoring therapy with L-asparaginase. Model of drug-induced antithrombin III deficiency]
Aphasia
Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.
Arthritis
Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase.
Arthritis, Experimental
Biochemical criteria for the evaluation of drug efficiency on adjuvant arthritis and nephrotoxic serum nephritis in the rat: studies with phenylbutazone, L-Asparaginase, colchicine, lysine acetylsalicylate, and pyridinol carbamate.
Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase.
Arthritis, Rheumatoid
Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase.
Arthus Reaction
Acrylic microspheres in vivo V: Immunological properties of immobilized asparaginase in microparticles.
Blast Crisis
Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome.
Treatment of the lymphoid blast crisis of chronic myeloid leukemia.
Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Brain Diseases
Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy.
L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.
Neurological complications of antineoplastic therapy.
Neurological complications of chemotherapy to the central nervous system.
Brain Edema
Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient.
Breast Neoplasms
Antiproliferative activity of L-asparaginase of Tetrahymena pyriformis on human breast cancer cell lines.
Cerebrovascular complications in cancer patients.
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
Clinical characteristics of Japanese patients with severe hypertriglyceridemia.
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.
Purification and biotechnological applications of L-asparaginase from newly isolated Bacillus halotolerans OHEM18 as antitumor and antioxidant agent.
Yarrowia lipolytica L-asparaginase inhibits the growth and migration of lung (A549) and breast (MCF7) cancer cells.
Burkitt Lymphoma
L-asparaginase and Burkitt's lymphoma.
Safety of Eicosapentaenoic Acid in Cancer Treatment: Effect on Cancer Cells and Chemotherapy in Vitro.
The effect of Yarrowia lipolytical-asparaginase on apoptosis induction and inhibition of growth in Burkitt's lymphoma Raji and acute lymphoblastic leukemia MOLT-4 cells.
Carcinogenesis
Studies on inhibition of viral oncogenesis. II. Inhibitory effect of L-asparaginase, clam liver extract and methotrexate on rous sarcoma virus focus formation.
Carcinoma
Bioprocess development for L-asparaginase production by Streptomyces rochei, purification and in-vitro efficacy against various human carcinoma cell lines.
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase.
Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase.
Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin.
Phase II study of L-asparaginase in the treatment of pancreatic carcinoma.
Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4.
Prolonged control of hypoglycaemia by L-asparaginase in islet cell carcinoma producing insulin and gastrin.
Sensitivity of cultured pancreatic carcinoma cells to Acinetobacter glutaminase-asparaginase.
Update in Systemic and Targeted Therapies in Gastrointestinal Oncology.
Carcinoma, Bronchogenic
An analysis of comparative trails of L-asparaginase (NSC-109929), cyclophosphamide and placebo in patients with inoperable bronchogenic carcinoma using corrected survival estimates.
Carcinoma, Ehrlich Tumor
Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model.
Carcinoma, Hepatocellular
Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells.
L-Asparaginase and Inhibitors of Glutamine Synthetase Disclose Glutamine Addiction of ?-Catenin-Mutated Human Hepatocellular Carcinoma Cells.
Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4.
Purification and biotechnological applications of L-asparaginase from newly isolated Bacillus halotolerans OHEM18 as antitumor and antioxidant agent.
The synergistic effect of hypoglycemia and L-asparaginase upon transplantable hepatomas of varying growth rates.
Carcinoma, Islet Cell
Prolonged control of hypoglycaemia by L-asparaginase in islet cell carcinoma producing insulin and gastrin.
Carcinosarcoma
[Results of an experimental study of the antitumor activity of 1-asparaginase from E. coli and Erw. carotovora]
Cerebral Hemorrhage
The role of drugs in the etiology of stroke.
[Fatal central nervous system hemorrhage during acute lymphoblastic leukemia induction].
Cerebral Infarction
Cerebral infarction in a patient with acute lymphoblastic leukemia after fresh-frozen plasma replacement during L-asparaginase therapy.
Chickenpox
Concomitant Use of Acyclovir and Intravenous Immunoglobulin Rescues an Immunocompromised Child With Disseminated Varicella Caused Multiple Organ Failure.
Choledochal Cyst
Pancreatic disorders in infancy and childhood: experience with 92 cases.
Cholestasis
Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia.
Colorectal Neoplasms
Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4.
Coma
Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient.
Communicable Diseases
Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia.
The morpheein model of allosterism: a remedial step for targeting virulent l-asparaginase.
Confusion
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia.
Conjunctivitis
Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.
Coronary Thrombosis
[Distal coronary thrombosis during l-asparaginase treatment for an acute lymbloblastic leukaemia.]
Dermatomyositis
Clinical studies with L-asparaginase in dermatomyositis.
Diabetes Mellitus
Diabetes mellitus and pancreatitis as a complication of L-asparaginase therapy.
Diabetes mellitus secondary to L-asparaginase therapy.
Hyperglucagonemia in L-asparaginase induced diabetes mellitus.
L-Asparaginase diabetes mellitus in rabbits: differing effects of two different schedules of L-asparaginase administration.
Relative hyperglucagonemia in L-asparaginase-and prednisone-induced glucose intolerance in management of acute lymphocytic leukemia.
The prevalence and etiology of extreme hypertriglyceridemia in children: Data from a tertiary children's hospital.
Transient diabetes mellitus secondary to L-asparaginase therapy in acute leukemia.
[Transient diabetes mellitus during L-asparaginase therapy]
[Transient diabetes mellitus induced by L-asparaginase in a patient with acute myeloblastic leukemia (author's transl)]
[Transient diabetes mellitus related to L-asparaginase therapy]
[Transient diabetes mellitus with ketoacidosis in a child during the treatment of acute lymphoblastic leukemia with L-asparaginase]
Diabetic Ketoacidosis
Acute Pancreatitis and Diabetic Ketoacidosis following L-Asparaginase/Prednisone Therapy in Acute Lymphoblastic Leukemia.
Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase.
Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis.
Diabetic ketoacidosis secondary to L-asparaginase in acute lymphoblastic leukaemia.
Diabetic ketoacidosis with L-asparaginase therapy.
Hyperglycemia induced by chemotherapeutic agents used in acute lymphoblastic leukemia: report of three cases.
Study of beta-cell function and erythrocyte insulin receptors in a patient with diabetic ketoacidosis associated with L-asparaginase therapy.
[Diabetic ketoacidosis and hypofibrinogenemia as a complication of the treatment with L-asparaginase of acute lymphoblastic leukemia]
Disseminated Intravascular Coagulation
Cerebrovascular accidents in children with cancer.
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
[MRI abnormalities of the brain in neurologic complications following treatment of cancer in children]
[Protein C, protein S]
[Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22)].
Encephalomyelitis, Autoimmune, Experimental
Further studies on the inhibition of allergic encephalomyelitis by L-asparaginase.
L-asparaginase in experimental auto-immune disease: inhibition of allergic encephalomyelitis.
Endocarditis
Staphylococcal endocarditis presenting with a renal infarct in a patient with acute lymphoblastic leukemia.
Endometrial Neoplasms
l-Asparaginase: aspiring for better outcomes in endometrial cancer.
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Enterocolitis, Neutropenic
[Surgery for neutropenic enterocolitis, a complication in acute lymphoblastic leukemia]
Enzootic Bovine Leukosis
Treatment of bovine lymphosarcoma with L-asparaginase.
[In vitro studies using E. coli L-asparaginase on lymphatic cells of bovine leukemia and various transplantation tumors]
Exanthema
An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase.
Fatty Liver
Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia.
Febrile Neutropenia
L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
Fibrosarcoma
Antitumor activity of L-asparaginase from Cylindrocarpon obtusisporum MB-10 and its effect on the immune system.
Molecular and genetic characterization of human cell lines resistant to L-asparaginase and albizziin.
Gallstones
Pancreatic disorders in infancy and childhood: experience with 92 cases.
Glioblastoma
Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy Against Brain Tumors.
L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells.
Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
Glioma
Hypersensitivity of rat glioma sublines with acquired ACNU resistance to L-asparaginase.
Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
Glomerulonephritis
[Effect of L-Asparaginase on Masugi's glomerulonephritis in the rat]
Glycosuria
[Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase]
Heart Defects, Congenital
Pediatric thromboembolism: a national survey in Japan.
Heart Failure
Risk factors for the development of hospital-acquired pediatric venous thromboembolism-Dealing with potentially causal and confounding risk factors using a directed acyclic graph (DAG) analysis.
Hematologic Diseases
Differences in the blast cells sensitivity to cytostatic drugs in various acute leukemia types and their clinical implications.
Hematologic Neoplasms
Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis.
High efficacy of monomethoxypolyethylene glycol-conjugated L-asparaginase (PEG2-ASP) in two patients with hematological malignancies.
[Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]
[Transient diabetes mellitus related to L-asparaginase therapy]
Hemianopsia
[Homonymous lateral hemianopsia revealing cerebral thrombophlebitis. Role of a deficiency of protein S induced by l-asparaginase]
Hemorrhoids
[Recurrent thrombosed external hemorrhoids due to L-asparaginase administration in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient].
Hemostatic Disorders
[Hemostatic disorders in the treatment of leukoblastosis with L-asparaginase (crasnitin)]
Hepatic Encephalopathy
Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient.
Hepatitis
[Fulminant hepatitis possibly caused by L-asparaginase during induction chemotherapy in a patient with acute lymphoblastic leukemia].
Hepatomegaly
Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia.
Histopathological features of L-asparaginase-induced liver disease.
Histiocytosis
A desensitization protocol in children with L-asparaginase hypersensitivity.
Histiocytosis, Langerhans-Cell
A desensitization protocol in children with L-asparaginase hypersensitivity.
Hodgkin Disease
Microbial L-asparaginase: purification, characterization and applications.
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis.
Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Hypercholesterolemia
Hypertriglyceridemia and hypercholesterolemia induced by L-asparaginase.
Hyperglycemia
Acute Hyperglycemia Associated with Anti-Cancer Medication.
An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase.
Endocrine complications in pediatric patients with acute lymphoblastic leukemia.
Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemia.
Hyperglycemia and acute parotitis related to L-asparaginase therapy.
Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors.
Hyperglycemia induced by chemotherapeutic agents used in acute lymphoblastic leukemia: report of three cases.
Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.
Incidence of Hyperglycemia during Induction of Remission Phase of Pediatric Acute Lymphoblastic Leukemia.
L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
L-asparaginase related hyperglycemia.
Medication-induced hyperglycemia: pediatric perspective.
Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia.
Nonketotic hyperglycemia due to prednisone (NSC-10023) following ketotic hyperglycemia due to L-asparaginase (NSC-109229) plus prednisone.
Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.
Relative hyperglucagonemia in L-asparaginase-and prednisone-induced glucose intolerance in management of acute lymphocytic leukemia.
Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone.
The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL).
Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.
[Hyperglycemia as a side effect of using L-asparaginase in children with acute lymphoblastic leukemia (ALL]
Hyperlipidemias
Factors with conformational effects on haemostatic serpins: implications in thrombosis.
Severe hyperlipidemia in a case of acute lymphoblastic leukemia.
Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with L-asparaginase and prednisone.
Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.
[Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia]
[L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia]
Hypersensitivity
A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
A critical review on properties and applications of microbial l-asparaginases.
A desensitization protocol in children with L-asparaginase hypersensitivity.
A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand.
Acute life-threatening toxicity of cancer treatment.
Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses.
Adverse reactions of L-asparaginase.
Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Allergic reactions to asparaginase: Retrospective cohort study in pediatric patients with acute lymphoid leukemia.
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase.
An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
An urchin-like helical polypeptide-asparaginase conjugate with mitigated immunogenicity.
Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Asparaginase immune complexes induce Fc-?RIII-dependent hypersensitivity in naive mice.
Asparaginase-associated pancreatitis in children.
Asparaginase: an old drug with new questions.
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
Circumventing the side effects of L-asparaginase.
Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Comparative pharmacokinetic studies of three asparaginase preparations.
Delayed allergic reactions following intramuscular L-asparaginase.
Delayed-type hypersensitivity in response to L-asparaginase in a case of acute lymphoblastic leukemia.
Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemia.
Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
Expression of CD203c on basophils as a marker of immunoglobulin E-mediated l-asparaginase allergy.
Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice.
Hypersensitivity of rat glioma sublines with acquired ACNU resistance to L-asparaginase.
Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center.
Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study .
Incidence and Management of Toxicity Associated with LAsparaginase in the Treatment of ALL and NK/TCell Lymphoma: an Observational Study.
Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase.
L-asparaginase and PEG asparaginase--past, present, and future.
L-Asparaginase and Steroids-associated Hypertriglyceridemia Successfully Treated With Plasmapheresis in a Child With Acute Lymphoblastic Leukemia.
L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
L-asparaginase used with cytosine arabinoside in treatment of childhood acute lymphocytic leukemia refractory to vincristine and prednisone.
L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma.
l-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.
Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia.
Monitoring of Anti-L-Asparaginase Antibody and L-Asparaginase Activity Levels in a Pediatric Patient With Acute Lymphoblastic Leukemia and Hypersensitivity to Native Escherichia coli L-Asparaginase During Desensitization Courses.
Monolith and coating enzymatic microreactors of l-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
New chemotherapy treatment options and implications for nursing care.
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.
Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma.
Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Pegaspargase: an alternative?
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood ALL.
Production of a novel N-terminal PEGylated crisantaspase.
Prolonged second remissions in childhood acute lymphocytic leukemia: a report from the Childrens Cancer Study Group.
Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Rapid desensitization for L-asparaginase hypersensitivity.
Recent Strategies and Applications for l-Asparaginase Confinement.
Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.
Screening and characterization of extracelluar L-asparaginase producing Bacillus subtilis strain hswx88, isolated from Taptapani hotspring of Odisha, India.
Screening and optimizing fermentation production of L-asparaginase by Aspergillus terreus strain S-18 isolated from the Brazilian Caatinga Biome.
Suppression of skin hypersensitivity and antibody formation by L-asparaginase.
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization.
The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia.
The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Therapeutic l-asparaginase: upstream, downstream and beyond.
Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.
Treatment of L-asparaginase allergic reaction.
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
[Allergic complications of L-asparaginase therapy in children with acute lymphoblastic leukaemia].
[Allergic reactions and antibody formation in children and adults treated with L-asparaginase for leukemia]
[Allergic reactions in treatment with L-asparaginase. Significance of specific IgE antibodies]
[Extracorporeal treatment with L-asparaginase (author's transl)]
[Hypersensitivity reactions to chemotherapeutic antineoplastic agents]
[Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia]
Hypersensitivity, Immediate
Atopic hypersensitivity to L-asparaginase. Resistance to immunosuppression.
Hyperthyroidism
Transient hyperthyroidism following L-asparaginase therapy for acute lymphoblastic leukemia.
Hypertriglyceridemia
Acarbose is an effective treatment for severe hypertriglyceridemia secondary to l-asparaginase and dexamethasone.
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.
Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.
Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma.
Clinical characteristics of Japanese patients with severe hypertriglyceridemia.
Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature.
Hypertriglyceridemia and hypercholesterolemia induced by L-asparaginase.
L-Asparaginase and Steroids-associated Hypertriglyceridemia Successfully Treated With Plasmapheresis in a Child With Acute Lymphoblastic Leukemia.
L-asparaginase induced severe hypertriglyceridemia in acute lymphoblastic leukemia with 11q23 abnormality.
Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy.
[Hypertriglyceridemia, Discorvered on a Pseudohyponatremia, Induced by L-asparaginase in the Treatment of B Acute Lymphoblastic Leukemia in Child].
[Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia]
[Successful readministration of L-asparaginase after development of severe hypertriglyceridemia in a young adult with T-cell acute lymphoblastic leukemia].
Hypoalbuminemia
Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.
Hypocalcemia
[Hypoparathyroidismus following L-asparaginase and vaccinia virus infection. Effect of hypocalcemia on phagocytosis and the function of lymphocytes]
Hypoglycemia
Control of hypoglycemia with L-asparaginase in a patient with islet cell cancer.
Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report.
L-asparaginase induced hypoglycemia in a case of acute lymphoblastic leukemia: a patient report.
The synergistic effect of hypoglycemia and L-asparaginase upon transplantable hepatomas of varying growth rates.
Hypoparathyroidism
[Hypoparathyroidism following application of L-asparaginase in the rabbit]
[Hypoparathyroidismus following L-asparaginase and vaccinia virus infection. Effect of hypocalcemia on phagocytosis and the function of lymphocytes]
Hypoprothrombinemias
Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation.
Hypothyroidism
Clinical characteristics of Japanese patients with severe hypertriglyceridemia.
Transient secondary hypothyroidism and thyroxine binding globulin deficiency in leukemic children during polychemotherapy: an effect of L-asparaginase.
Infections
Helicobacter pylori L-asparaginase: A Novel Bacterial Antigen that May Contribute to Infection Detection.
Pancreatitis after renal transplantation.
Pepper asparagine synthetase 1 (CaAS1) is required for plant nitrogen assimilation and defense responses to microbial pathogens.
Risk factors for the development of hospital-acquired pediatric venous thromboembolism-Dealing with potentially causal and confounding risk factors using a directed acyclic graph (DAG) analysis.
Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.
[Clinical analysis of cerebral venous sinus thrombosis in six children].
[Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]
Intracranial Hemorrhages
Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia.
Intracranial Thrombosis
Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.
Childhood non-Hodgkin's lymphoma--results of treatment with ALL high-risk protocol.
Neurosurgical management of L-asparaginase induced haemorrhagic stroke.
Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy.
[Cerebral thrombosis in a child with acute lymphocytic leukemia during L-asparaginase therapy]
[Homonymous lateral hemianopsia revealing cerebral thrombophlebitis. Role of a deficiency of protein S induced by l-asparaginase]
[Neurologic complications during chemotherapy of children with acute lymphoid leukemia]
Ischemic Attack, Transient
Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.
Ketosis
Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.
Persistent diabetes and ketoacidosis due to L-asparaginase therapy.
[Transient diabetes mellitus with ketoacidosis in a child during the treatment of acute lymphoblastic leukemia with L-asparaginase]
Leishmaniasis
L-Asparaginase as a new molecular target against leishmaniasis: insights into the mechanism of action and structure-based inhibitor design.
Lethargy
Asparaginase-associated pancreatitis in a dog.
Leukemia
A child with myeloid/natural killer cell precursor acute leukemia treated successfully with acute myeloid leukemia-oriented chemotherapy incorporating l-asparaginase.
A desensitization protocol in children with L-asparaginase hypersensitivity.
A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
Abnormal glucose tolerance in children with acute leukemia. Effect of induction chemotherapy including L-asparaginase.
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Acute mixed lineage leukemia in children: The experience of St. Jude Children's Research Hospital.
Addition of rubidomycin to induction treatment with vincristine, prednisone, and L-asparaginase in standard-risk childhood acute lymphocytic leukemia (study ALL V): a report on behalf of the Dutch Childhood Leukemia Study Group.
Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.
Aggressive NK-cell leukemia: Therapeutic potentials of L-asparaginase and allogeneic hematopoietic stem cell transplantation.
Altered Fibrinolysis in Hematological Malignances.
Amino acid content of L5178Y and L5178Y/L-ASE cells after L-asparaginase treatment.
An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase.
Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.
Antileukemic effect of L-aspartyl-hydrazine.
Antitumor effect of L-alanosine (NSC 153553) on sensitive and resistant sublines of murine leukemias.
Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis.
Asparaginase decreases clotting factors in vitro: a possible pitfall?
Asparaginase immune complexes induce Fc-?RIII-dependent hypersensitivity in naive mice.
Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion.
Asparagine synthetase is partially localized to the plasma membrane and upregulated by L-asparaginase in U937 cells.
Asparagine synthetase: a new potential biomarker in ovarian cancer.
Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1 driven B-cell precursor acute lymphoblastic leukemia.
Biochemical characterization of a novel L-Asparaginase with low glutaminase activity from Rhizomucor miehei and its application in food safety and leukemia treatment.
Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase.
Cerebrovascular accidents in children with cancer.
Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.
Characterization of inhibitors acting at the synthetase site of Escherichia coli asparagine synthetase B.
Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Chemical metabolic inhibitors for the treatment of blood-borne cancers.
Chemotherapy and radiotherapy--competitors or partners?
Clinical pharmacology of intramuscularly administered L-asparaginase.
Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia.
Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.
Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
Combination therapy involving L-asparaginase in acute leukemia.
Comparison of daily and twice-weekly schedule of L-asparaginase in childhood leukemia.
Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia.
Confinement of Therapeutic Enzymes in Selectively Permeable Polymer Vesicles by Polymerization-Induced Self-Assembly (PISA) Reduces Antibody Binding and Proteolytic Susceptibility.
Correlation between decreased apoptosis and multidrug resistance (MDR) in murine leukemic T cell lines.
Cytoenzymochemical effects of some antiblastic drugs and prediction of response to chemotherapy in acute leukemias.
De novo transcriptome of the cosmopolitan dinoflagellate Amphidinium carterae to identify enzymes with biotechnological potential.
Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.
Diabetic ketoacidosis with L-asparaginase therapy.
Dietary thiamine influences l-asparaginase sensitivity in a subset of leukemia cells.
Dysmetabolic and neurological complications in leukemia patients treated with L-asparaginase.
E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children.
Early detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography: a preliminary report.
Effect of chemical modification with carboxymethyl dextran on kinetic and structural properties of L-asparaginase.
Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.
Effect of l-asparaginase and asparagine deprivation on RNA metabolism in mouse leukemia L 5178Y cells in suspension culture.
Effect of L-Asparaginase Combined with Vincristine and Prednisolone on Acute Myeloblastic Leukemia (M0) Associated with Non-Hodgkin Lymphoma.
Effect of L-asparaginase therapy upon serum pseudocholinesterase and ceruloplasmin levels in patients with acute leukemia.
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells.
Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group.
Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
Effects of L-asparaginase on the two cases of acute leukemia with mediastinal tumors as initial signs.
Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase.
Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.
Enzymes as agents for the treatment of disease.
Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.
Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression.
Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemia.
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.
Evaluation of prednisolone and vincristine with and without L-asparaginase in acute lymphatic leukemia of childhood.
Experimental studies with L-asparaginase in mouse leukemias.
Extracellular expression and single step purification of recombinant Escherichia coli L-asparaginase II.
Genetic and metabolic engineering approaches for the production and delivery of L-asparaginases: An overview.
Genistein enhances the effects of L-asparaginase on inducing cell apoptosis in human leukemia cancer HL-60 cells.
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Glutamine-dependent asparagine synthetase from leukemia cells. Chloride dependence, mechanism of action, and inhibition.
Greater decrease of fibrinogen as compared to antithrombin III in L-asparaginase treated leukemia patients.
Growth inhibitory and proapoptotic effects of l-asparaginase from Fusarium culmorum ASP-87 on human leukemia cells (Jurkat).
Heterologous expression and purification of active L-asparaginase I of Saccharomyces cerevisiae in Escherichia coli host.
High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study.
Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase.
Hyperglycemia induced by chemotherapeutic agents used in acute lymphoblastic leukemia: report of three cases.
Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia.
Immobilization of l-Asparaginase on Carrier Materials: A Comprehensive Review.
Immunological and pharmacological characterization of poly-DL-alanyl-modified Erwinia carotovora L-asparaginase.
In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Induction and characteristics of resistance to L-asparaginase (NSC-109229) in mouse leukemia L5178Y.
Induction of remission with l-Asparaginase, cyclophosphamide, cytosine arabinoside, and prednisolone in adult patients with acute leukemia.
Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
Inhibition of leukemias in man by L-asparaginase.
Inhibitors of L-asparagine synthetase, in vitro.
Insights into the microbial L-asparaginases: from production to practical applications.
L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia.
L-asparaginase activity in acute nonlymphocytic leukemia.
L-asparaginase and PEG asparaginase--past, present, and future.
L-asparaginase effects on intact murine leukemia cells and on isolated cell plasma membranes.
l-Asparaginase from Aspergillus spp.: production based on kinetics, thermal stability and biochemical characterization.
L-asparaginase in treatment of acute leukemia in children.
L-asparaginase induced alteration of amethopterin (methotrexate) activity in mouse leukemia L5178Y.
L-asparaginase induces in AML U937 cells apoptosis via an AIF-mediated mechanism.
L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia.
L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group.
L-asparaginase therapy in leukemia.
L-asparaginase therapy with concomitant cranial venous thrombosis: can MRI help avoiding stroke.
L-asparaginase treatment in acute leukemia of childhood.
L-asparaginase treatment of acute myeloblastic leukemia.
L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.
L-asparaginase--antileukemia agent.
L-asparaginase-antileukemia agent.
L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.
L-Asparaginase: human toxicology and single agent activity in nonleukemic neoplasms.
L-asparaginase: old dog, more tricks and leukemia: not simply a liquid tumor.
Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase.
Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia.
Methotrexate/L-asparaginase combination chemotherapy for patients with acute leukemia in relapse: a study of 36 children.
Optimization and purification of l-asparaginase from fungi: A systematic review.
Pancreatitis in children: clinical analysis of 61 cases in southern Taiwan.
Partial purification and anti-leukemic activity of L-asparaginase enzyme of the actinomycete strain LA-29 isolated from the estuarine fish, Mugil cephalus (Linn.).
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia.
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme asparaginase by biocompatible multilayered polyelectrolyte microcapsules.
Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4.
Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.
Purification and biotechnological applications of L-asparaginase from newly isolated Bacillus halotolerans OHEM18 as antitumor and antioxidant agent.
Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties.
Radiation in the treatment of meningeal leukemia.
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
Remission induction with L-asparaginase, vincristine, and prednisone in children with acute nonlymphoblastic leukemia.
Repeated use of L-asparaginase in multi-drug therapy of childhood leukemia.
Response to highly purified L-asparaginase during therapy of acute leukemia.
Result of a cooperative study with L-asparaginase in human leukemias. Report of the section "oncology" of the Paul-Ehrlich-Society for Chemotherapy.
Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone.
Sagittal sinus thrombosis due to L-asparaginase.
Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia.
Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias.
Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse.
Serum amino acid levels in leukemic mice after L-asparaginase treatment.
Short courses of cytosine arabinoside and L-asparaginase in children with acute leukemia.
Some clinical observations on the treatment with L-asparaginase of the acute leukemias.
Spleen focus assays with a mouse leukemia virus in mice treated with actinomycin D, L-asparaginase or rifampicin.
Stability of L-asparaginase: an enzyme used in leukemia treatment.
Staphylococcal L-asparaginase: antilymphoma and immunosuppressive action.
Studies of resistance to L-asparaginase in human leukemia.
Study of cytosine arabinoside (NSC-63878) synchronization plus vincristine (NSC-67574), prednisone (NSC-10023), and L-asparaginase (NSC-109229) for remission induction in advanced acute leukemia in children.
Successful disease control with l-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure.
Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase.
Suppression of Rauscher virus-induced leukemia by L-asparaginase.
Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer.
Targeting extracellular nutrient dependencies of cancer cells.
Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.
The clinical toxicities of L-asparaginase in treatment of leukemia and lymphoma.
The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
The effect of L-asparaginase on the nucleic acid metabolism and cell cycle of human leukemia cells.
The place of the L-asparaginase in the treatment of acute leukemias.
The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
Therapy of adult acute leukemia with daunorubicin and L-asparaginase.
Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase. Results of a Cancer and Leukemia Group B Study.
Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase.
Thiol-maleimide poly(ethylene glycol) crosslinking of L-asparaginase subunits at recombinant cysteine residues introduced by mutagenesis.
Thrombosis in children receiving L-asparaginase. Determining patients at risk.
Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.
Transient diabetes mellitus secondary to L-asparaginase therapy in acute leukemia.
Treatment of a child with myeloid/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation.
Treatment of acute leukemia with L-asparaginase.
Treatment of adult leukemia with L-asparaginase (NSC-109229).
Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Tumoricidal potential of nutritional manipulations.
Ultrastructural changes in murine leukemia cells exposed to l-asparaginase in vitro.
Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Venous thromboembolism incidence in hematologic malignancies.
ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase.
[4 cases of acute leukemia treated with L-asparaginase]
[Adverse reactions to L-asparaginase in children with acute lymphatic leukemia]
[Allergic reactions and antibody formation in children and adults treated with L-asparaginase for leukemia]
[Attempts at treatment of acute leukemia with L-asparaginase]
[Bacterial recombinant L-asparaginases: properties, structure and anti-proliferative activity].
[Cellular test system for studying the biological properties of preparations with L-asparaginase activity]
[Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)]
[Combined treatment of acute leukemia with L-asparaginase and daunomycin]
[Complete remission achieved by L-asparaginase, vincristine and prednisolone (LVP) therapy in secondary leukemia (M5a type) with an MLL gene rearrangement]
[Complete remission obtained in refractory acute lymphocytic leukemia using high-dose cytosine arabinoside combined with low-dose L-asparaginase]
[Complete remission of lymphosarcoma cell leukemia with BACOP and L-asparaginase therapy--report of a case (author's transl)]
[Current national and international status of supportive therapy for the coagulopathy associated with L-asparaginase containing regimen for acute lymphoblastic leukemia].
[Effect of L-asparaginase in small dosage on advanced leukemia in children (author's transl)]
[Efficiency of treatment of adult patients with acute T-lymphoblastic leukemia according to the ALL-2009 protocol of the Russian Acute Leukemia Study Group].
[Electron microscopic observations on the effect of L-asparaginase at transplanted leukemias of the mouse]
[Evaluation of new antileukemic agents, with special reference to L-asparaginase, and cyclic maintenance therapy in acute leukemia]
[First results of the treatment of acute leukemia with L-asparaginase]
[High-dose cytosine arabinoside and L-asparaginase in the treatment of refractory or recurrent acute non-lymphoblastic leukemia]
[Inhibition of lymphocyte transformation by L-asparaginase in acute leukemia]
[Inhibition of synthesis of protein and nucleic acid in mouse and human leukemia cells by L-asparaginase in vitro]
[Initial results of the use of L-asparaginase in acute leukemia in childhood]
[L-asparaginase and leukemia]
[L-asparaginase in acute leukemia refractory to treatment]
[L-asparaginase in advanced acute leukemia in children]
[L-asparaginase in blast leukemia]
[L-asparaginase in combined treatment of acute leukemia not affecting the bone marrow]
[L-asparaginase in leukemia]
[L-asparaginase in the 12th relapse of acute lympoblastic leukemia in a child]
[L-asparaginase in the treatment of acute leukemia in children]
[L-asparaginase in the treatment of acute leukemias. Biological aspects]
[L-asparaginase in the treatment of acute leukemias]
[L-Asparaginase in the treatment of acute leukemia]
[L-asparaginase in the treatment of leukemia]
[L-asparaginase in the treatment of solid tumors and leukemia]
[L-asparaginase in the treatment of the acute leukemias. Biological aspects]
[L-asparaginase therapy against hybrid leukemia: a case report]
[L-asparaginase therapy in 14 cases of acute lymphatic leukemia observed at the Clinica Pediatrica di Modena]
[Metabolic complications of the treatment of acute leukemia with L-asparaginase (apropos of 147 cases)]
[Progress in researches on anti-tumor agent L-asparaginase for treatment of leukemia]
[Progress in researches on L-asparaginase targeted to childhood leukemia]
[Relationship between asparagine synthetase expression level and cell sensitivity to L-asparaginase in human leukemic cell lines]
[Results of L-asparaginase therapy in acute leukemia of the adult]
[Results of L-asparaginase therapy in acute leukemias]
[Results of treatment of children with acute lymphatic leukemia (ALL) according to the ALL V protocol of the Netherlands Working Group on Leukemia in Children]
[Reversible posterior leukoencephalopathy syndrome probably caused by L-asparaginase]
[Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma]
[Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia]
[Study of tumor cells sensitivity in patients with acute leukemia to cytokines and their combined use with drugs in vitro by MTT analysis]
[Successful readministration of L-asparaginase after development of severe hypertriglyceridemia in a young adult with T-cell acute lymphoblastic leukemia].
[Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22)].
[Surgery for neutropenic enterocolitis, a complication in acute lymphoblastic leukemia]
[The hematopoietic regeneration in acute lymphatic leukemia in the child under L-asparaginase treatment]
[The L-asparaginase in the treatment of leukemias]
[The treatment of acute leukemias with L-asparaginase]
[Therapeutic effects and side effects of L-asparaginase on acute leukemia and multiple myeloma]
[Therapeutic results and prognostic factors in acute lymphatic leukemia in the adult]
[Transient diabetes mellitus induced by L-asparaginase in a patient with acute myeloblastic leukemia (author's transl)]
[Treatment of acute leukemia with L-asparaginase]
[Treatment of acute leukemia with the L-asparaginase. Preliminary results based on 84 cases]
[Treatment of acute leukemias with L-asparaginase. Preliminary results]
[Treatment of adult acute leukemia with a combination of cytosine arabinoside, vincristine, 6-mercaptopurine, prednisolone, and L-asparaginase (author's transl)]
[Treatment of leukemia with L-asparaginase]
[Use of L-asparaginase (Krasnitin) in children with acute leukemia during repeated exacerbations]
[Use of L-asparaginase in the treatment of leukemia. Experiences from 4 Dutch hospitals]
[Use of L-asparaginase in therapy with special reference to acute lymphatic leukemia]
Leukemia P388
Antitumor effect of L-alanosine (NSC 153553) on sensitive and resistant sublines of murine leukemias.
Leukemia, Biphenotypic, Acute
[Reversible posterior leukoencephalopathy syndrome probably caused by L-asparaginase]
Leukemia, Large Granular Lymphocytic
Successful disease control with l-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure.
Leukemia, Lymphoid
Acrylic microspheres in vivo VI: antitumor effect of microparticles with immobilized L-asparaginase against 6C3HED lymphoma.
Glutaraldehyde-Mediated Synthesis of Asparaginase-Bound Maghemite Nanocomposites: Cytotoxicity against Human Colon Adenocarcinoma Cells.
L-Asparaginase: effect on 7S gamma globulin extents and germinal centers in spleen and lymph-nodes.
Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase.
Methotrexate followed by L-asparaginase for the treatment of acute non lymphoid leukemia.
[High molecular weight L-asparaginase derivatives based on a water-soluble carboxymethyl cellulose: biological properties]
[L-Asparaginase therapy in chemotherapy-resistant acute lymphocytic leukemias (author's transl)]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome.
Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen.
Treatment of L-asparaginase allergic reaction.
Treatment of the lymphoid blast crisis of chronic myeloid leukemia.
Leukemia, Myeloid
Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse.
Leukemia, Myeloid, Acute
Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to L-asparaginase.
Antiproliferative effects of L-asparaginase in acute myeloid leukemia.
Effect of L-Asparaginase Combined with Vincristine and Prednisolone on Acute Myeloblastic Leukemia (M0) Associated with Non-Hodgkin Lymphoma.
Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1.
Effects of L-asparaginase in acute myelocytic leukemia.
Enzymes as agents for the treatment of disease.
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study.
Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-Asparaginase.
L-asparaginase activity in acute nonlymphocytic leukemia.
L-asparaginase and PEG asparaginase--past, present, and future.
L-asparaginase in treatment of acute leukemia in children.
L-asparaginase treatment of acute myeloblastic leukemia.
Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia.
Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.
Remission induction with L-asparaginase, vincristine, and prednisone in children with acute nonlymphoblastic leukemia.
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Thiol-maleimide poly(ethylene glycol) crosslinking of L-asparaginase subunits at recombinant cysteine residues introduced by mutagenesis.
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
[The apoptosis-inducing potential of L-asparaginase in acute myeloid leukemia cells].
[Transient diabetes mellitus induced by L-asparaginase in a patient with acute myeloblastic leukemia (author's transl)]
Leukemia, T-Cell
Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).
Growth inhibitory and proapoptotic effects of l-asparaginase from Fusarium culmorum ASP-87 on human leukemia cells (Jurkat).
Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia.
Leukoencephalopathies
[Posterior reversible leukoencephalopathy syndrome induced by L-asparaginase in a teenage female diagnosed with acute lymphoblastic leukemia].
[Reversible posterior leukoencephalopathy syndrome probably caused by L-asparaginase]
Lipidoses
Hepatic lipidosis associated with L-asparaginase treatment.
Liver Cirrhosis
Quantitation of plasma levels of tetranectin--effects of oral contraceptives, pregnancy, treatment with L-asparaginase and liver cirrhosis.
Liver Diseases
Histopathological features of L-asparaginase-induced liver disease.
L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
[Protein C, protein S]
Liver Failure
Fatal Liver Failure in an Adult Patient with Acute Lymphoblastic Leukemia following Treatment with L-Asparaginase.
Risk factors for the development of hospital-acquired pediatric venous thromboembolism-Dealing with potentially causal and confounding risk factors using a directed acyclic graph (DAG) analysis.
Successful disease control with l-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure.
Liver Neoplasms, Experimental
Potential inhibitors of L-asparagine biosynthesis. 5. Electrophilic amide analogues of (S)-2,3-diaminopropionic acid.
Lung Neoplasms
Randomized phase II comparison of methotrexate with or without L-asparaginase in non-small cell cancer of the lung.
Synthesis, characterization and synergistic activity of cerium-selenium nanobiocomposite of fungal l-asparaginase against lung cancer.
Yarrowia lipolytica L-asparaginase inhibits the growth and migration of lung (A549) and breast (MCF7) cancer cells.
Lupus Erythematosus, Systemic
[Treatment of systemic lupus erythematosus with L-asparaginase: considerations on a case]
Lymphohistiocytosis, Hemophagocytic
Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant.
Lymphoma
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
A pilot study evaluating changes in pancreatic lipase immunoreactivity concentrations in canines treated with L-asparaginase (ASNase), vincristine, or both for lymphoma.
A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type.
Acrylic microspheres in vivo VI: antitumor effect of microparticles with immobilized L-asparaginase against 6C3HED lymphoma.
Acute pancreatitis in association with L-asparaginase therapy: report of one case.
Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type.
Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.
Antitumor activity of L-asparaginase from Cylindrocarpon obtusisporum MB-10 and its effect on the immune system.
Antitumor effect of hippurate. An experimental study using various mouse tumor strains.
Asparaginase and MOPP treatment of dogs with lymphoma.
Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation.
Blastic natural killer cell lymphoma/leukaemia in a cat.
Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy.
Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma.
Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma.
Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.
Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.
Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
Comparison of combination l-asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi-centric T-cell or hypercalcaemic lymphoma.
Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrospective study.
Comparison of glycine metabolism in mouse lymphoma cells either sensitive or resistant to L-asparaginase.
Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL).
Concurrent Epstein-Barr virus associated NK/T cell lymphoma after immunosuppressive therapy for aplastic anemia: report of a case and review of literature.
Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase(*).
Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
E. coli-Derived L-Asparaginase Retains Enzymatic and Cytotoxic Activity In Vitro for Canine and Feline Lymphoma after Cold Storage.
Effects of L-asparaginase on plasma amino acid profiles and tumor burden in cats with lymphoma.
Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma.
Efficacy and adverse events of continuous l-asparaginase administration for canine large cell lymphoma of presumed gastrointestinal origin.
Efficacy and toxicosis of VELCAP-C treatment of lymphoma in cats.
Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma.
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Efficacy of pegaspargase in extra nodal natural killer/T-cell lymphoma nasal type: A case report from China.
Endovascular mechanical thrombectomy for superior sagittal sinus thrombosis in a patient with T-lymphoblastic lymphoma treated with L-asparaginase.
Enhancement in biological activity of L-asparginase by its conjugation on silica nanoparticles.
Enzyme therapy and immuno-adsorption by an extra-corporeal device.
Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.
Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Erratum for Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
Evaluation of Pgp (MDR1) immunohistochemistry in canine lymphoma - prognostic and clinical aspects.
Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo.
Failure of combination therapy with S-carbamyl-L-cysteine (SCC; NSC-102498) and L-asparaginase (NSC-109229) for L-asparaginase-resistant mouse lymphoma.
First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
Genetic and metabolic engineering approaches for the production and delivery of L-asparaginases: An overview.
Glutamate oxidation of 6C3HED lymphoma: effects of L-asparaginase on sensitive and resistant lines.
High efficacy of monomethoxypolyethylene glycol-conjugated L-asparaginase (PEG2-ASP) in two patients with hematological malignancies.
Immunological studies on modified enzymes. I. soluble L-asparaginase/mouse albumin copolymer with enzyme activity and substantial loss of immunogenicity.
In vitro immune monitoring of antibody response in dogs given chemoimmunotherapy for lymphoma.
Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.
Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity.
Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
Inhibition of lymphoma 6C3HED by L-asparaginase from Serratia marcescens.
Insights into the microbial L-asparaginases: from production to practical applications.
Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.
L-asparaginase and PEG asparaginase--past, present, and future.
L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis.
L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation.
L-asparaginase kills lymphoma cells by apoptosis.
L-Asparaginase, Doxorubicin, Vincristine, and Prednisolone (LHOP) Chemotherapy as a First-Line Treatment for Dogs with Multicentric Lymphoma.
L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
L-asparaginase: early findings and current studies on the metabolism of L-asparagine in lymphoma cells.
L-Asparaginase: effect on 7S gamma globulin extents and germinal centers in spleen and lymph-nodes.
L-asparaginyl-tRNA synthetase and L-asparagine synthetase activities of L-asparaginase-sensitive and -resistant forms of the mouse Gardner lymphoma 6C3HED.
Marked cytoreduction of a lymphocyte-rich mediastinal thymoma with neoadjuvant chemotherapy in a cat.
Massive uric acid crystalluria and cylinduria in a dog after l-asparaginase treatment for lymphoma.
Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
Nasal extranodal peripheral NK/T-cell lymphoma treated by the protocol NK/T-cell high-dose-methotrexate L-asparaginase dexamethasone.
Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma.
PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety.
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.
Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study.
Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: A case report.
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Phase 2 trial of "Sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma.
Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma.
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type.
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.
Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma.
Prospective evaluation of the safety of compounded bulk material L-asparaginase in dogs with lymphoma.
Response of intracerebral Gardner lymphoma to guinea pig L-asparaginase and Escherichia coli L-asparaginase.
Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases (1993-1997)
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Selective apoptosis of natural killer-cell tumours by l-asparaginase.
Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
Serum C-reactive protein concentrations in dogs with multicentric lymphoma undergoing chemotherapy.
Structure-Function Relationships and Clinical Applications of L-Asparaginases.
Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells.
Studies on the recombinant production and anticancer activity of thermostable L- asparaginase I from Pyrococcus abyssi.
Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma.
Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to L-asparaginase.
Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant.
Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.
Successful treatment with L-asparaginase based regimen for primary pulmonary NK/T cell lymphoma: a case report and review of the literature.
The clinical toxicities of L-asparaginase in treatment of leukemia and lymphoma.
The inhibition of lymphocyte blastogenesis by asparaginase: critical role of glutamine in both T and B lymphocyte transformation.
Therapy of a murine lymphoma with tumor-specific antiserum in combination with adriamycin, cyclophosphamide, or L-asparaginase.
Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.
Toxicity of L-asparaginase to resistant and susceptible lymphoma cells in vitro.
Treatment of a mouse lymphoma by L-asparaginase: success depends on the host's immune response.
Treatment of canine lymphoma with COPLA/LVP.
Treatment of feline lymphoma using a 12-week, maintenance-free combination chemotherapy protocol in 26 cats.
Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Ventricular fractional shortening in 108 dogs with malignant lymphoma undergoing chemotherapy with a cyclic combination protocol including doxorubicin.
[A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].
[Cellular test system for studying the biological properties of preparations with L-asparaginase activity]
[Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
[Complete remission obtained by sequential chemotherapy of L-asparaginase and continuous infusion of bleomycin (ABLE protocol) in a case of refractory diffuse large cell lymphoma of a paranasal origin]
[Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma].
[Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma]
[Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma]
Lymphoma, B-Cell
Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase.
[Complete remission obtained by sequential chemotherapy of L-asparaginase and continuous infusion of bleomycin (ABLE protocol) in a case of refractory diffuse large cell lymphoma of a paranasal origin]
Lymphoma, Large-Cell, Anaplastic
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Lymphoma, Non-Hodgkin
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography.
A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma.
Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent.
Asparaginase-associated pancreatitis in a dog.
Asparaginase-associated pancreatitis in children.
Changes in hemopoiesis of mice of the C3H strain following transplantation of Gardner lymphosarcoma and infection with LDH-virus. II. Spleen and bone marrow.
Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology.
Combination chemotherapy with L-asparaginase (EC-2) using P1798 lymphosarcoma.
Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
Early detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography: a preliminary report.
Effect of 9 alpha-fluoroprednisolone and L-asparaginase on uridine incorporation into ribosomal RNA of P1798 lymphosarcoma.
Effect of L-Asparaginase Combined with Vincristine and Prednisolone on Acute Myeloblastic Leukemia (M0) Associated with Non-Hodgkin Lymphoma.
Hyperglycemia and acute parotitis related to L-asparaginase therapy.
Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors.
Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease.
In vivo and in vitro effects of the L-asparaginase fraction of guinea pig serum on the 6C3HED ascites lymphosarcoma.
Increased serum trypsin and elastase-1 levels in patients undergoing L-asparaginase therapy.
Inhibition of thymidine and basic amino acid metabolism in P1798 lymphosarcoma by L-asparaginase.
L-asparaginase in treatment of acute leukaemia and lymphosarcoma.
L-asparaginase therapy and its complications in acute lymphoid leukaemia and generalized lymphosarcoma.
Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020.
Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia.
Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma.
Reversible MRI lesions due to pegaspargase treatment of non-Hodgkin's lymphoma.
Surgical pancreatic complications induced by L-asparaginase.
The effect of Yarrowia lipolytical-asparaginase on apoptosis induction and inhibition of growth in Burkitt's lymphoma Raji and acute lymphoblastic leukemia MOLT-4 cells.
The in vivo effects of semipermeable microcapsules containing L-asparaginase on 6C3HED lymphosarcoma.
Therapeutic l-asparaginase: upstream, downstream and beyond.
Therapy for Australian cats with lymphosarcoma.
Thiol-maleimide poly(ethylene glycol) crosslinking of L-asparaginase subunits at recombinant cysteine residues introduced by mutagenesis.
Treatment of bovine lymphosarcoma with L-asparaginase.
Treatment of lymphosarcoma in the dog with L-asparaginase.
[Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin's lymphoma. Report of the Polish Paediatric LeuKaemia/Lymphoma Study Group]
[Case of reticulum cell sarcoma treated with L-asparaginase and antibody to L-asparaginase]
[Cellular test system for studying the biological properties of preparations with L-asparaginase activity]
[Comparative evaluation of the clinical effectiveness of 3 preparations of E. coli L-asparaginase]
[Complete remission of lymphosarcoma cell leukemia with BACOP and L-asparaginase therapy--report of a case (author's transl)]
[L-asparaginase in combined treatment of lymphosarcoma in children]
[Non-Hodgkin's lymphoma with transient abnormal glucose tolerance by the administration of L-asparaginase and prednisolone]
[Repeated, 2-10 fold asparaginase treatments in children with lymphoproliferative diseases]
[Results of repeated L-asparaginase treatment in acute lymphoblastic leukemia and lymphosarcoma in children]
[Safety of polyethylene glycol conjugated L-asparaginase in patients with acute lymphoblastic leukemia and T cell non-Hodgkin lymphoma].
[Sequential combination of high-dose cytosine arabinoside and L-asparaginase in the treatment of refractory acute leukemia and malignant lymphoma]
[Update on L-asparaginase treatment in paediatrics.]
[VAMA salvage regimen (VP-16, ARA-C, MTX and L-asparaginase) in relapsed or resistant non-Hodgkin's lymphoma]
Lymphoma, T-Cell
Asparaginase and MOPP treatment of dogs with lymphoma.
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase.
T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report.
Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
L-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma.
L-asparaginase-induced complete response in a relapsed patient with Epstein-Barr virus and cytotoxic peripheral T-cell lymphoma not otherwise specified.
[A clinical observation of treatment of peripheral T-cell lymphoma with L-asparaginase-containing combination chemotherapy].
[The efficacy of L-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma]
Lymphoproliferative Disorders
Microbial L-asparaginase: purification, characterization and applications.
Malaria
Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer.
Massive Hepatic Necrosis
An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase.
Medulloblastoma
Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy Against Brain Tumors.
Melanoma
Extracorporeal perfusion treatment with immobilized L-asparaginase.
Inhibitation by L-asparaginase from E. coli of human malignant melanoma cells growing in vitro.
Mesenteric Ischemia
Cryoprecipitate-induced mesenteric venous thrombosis during L-asparaginase therapy for acute lymphoblastic leukaemia.
Microcephaly
Asparagine synthetase deficiency detected by whole exome sequencing causes congenital microcephaly, epileptic encephalopathy and psychomotor delay.
Mucositis
Childhood non-Hodgkin's lymphoma--results of treatment with ALL high-risk protocol.
Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.
Multiple Myeloma
A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
Amino acid depletion triggered by ?-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.
[Therapeutic effects and side effects of L-asparaginase on acute leukemia and multiple myeloma]
Myeloproliferative Disorders
Altered Fibrinolysis in Hematological Malignances.
Myocardial Infarction
Myocardial infarction in a patient with acute lymphoblastic leukemia during L-asparaginase therapy.
Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy.
The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood.
Myocardial Ischemia
Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy.
Neoplasm Metastasis
Asparagine bioavailability governs metastasis in a model of breast cancer.
Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles.
Duration of in vivo effects of L-asparaginase on experimental metastasis.
Enhancement of metastases by L-asparaginase in a mouse tumor system.
Enhancement of metastases by L-asparaginase in a mouse tumour system.
Enhancement of metastases by L-asparaginase in allogeneic and isogeneic mouse tumor systems.
Enzyme therapy and immuno-adsorption by an extra-corporeal device.
L-asparaginase and metastasis.
Prolonged control of hypoglycaemia by L-asparaginase in islet cell carcinoma producing insulin and gastrin.
SLC1A3 contributes to L-asparaginase resistance in solid tumors.
SOX12 promotes colorectal cancer cell proliferation and metastasis by regulating asparagine synthesis.
Yarrowia lipolytica L-asparaginase inhibits the growth and migration of lung (A549) and breast (MCF7) cancer cells.
Neoplasm, Residual
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
The Children Leukemia Group: 30 years of research and achievements.
[Results of the treatment of adult acute lymphoblastic leukemia according to ALL-2005 protocol as a basis for new trials]
Neoplasms
51 Cr-L-asparagine accumulation by tumors: the influence of L-asparaginase treatment.
A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
A critical review on properties and applications of microbial l-asparaginases.
A new pH indicator dye-based method for rapid and efficient screening of l-asparaginase producing microorganisms.
A Patent Review on the Use of L-asparaginase in the Treatment of Acute Lymphocytic Leukemia.
A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.
A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
A pilot study evaluating changes in pancreatic lipase immunoreactivity concentrations in canines treated with L-asparaginase (ASNase), vincristine, or both for lymphoma.
Acrylic microspheres in vivo VI: antitumor effect of microparticles with immobilized L-asparaginase against 6C3HED lymphoma.
Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study.
Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.
Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent.
Amino acid content of L5178Y and L5178Y/L-ASE cells after L-asparaginase treatment.
Amino acid depletion triggered by ?-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.
Anticancer activity of fungal L-asparaginase conjugated with zinc oxide nanoparticles.
Antilymphoma activity of L-asparaginase in vivo: clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth.
Antitumor activity of L-asparaginase from Cylindrocarpon obtusisporum MB-10 and its effect on the immune system.
Asparagine bioavailability governs metastasis in a model of breast cancer.
Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy Against Brain Tumors.
Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion.
Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia.
Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer.
Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Biochemical method of cancer control. L-asparaginase in cancer chemotherapy. A review.
Bioprocess development for L-asparaginase production by Streptomyces rochei, purification and in-vitro efficacy against various human carcinoma cell lines.
Blood lipid profiles in children with acute lymphoblastic leukemia.
Cell mass-dependent expression of an anticancer protein drug by tumor-targeted
Cell-based laboratory evaluation of coagulation activation by antineoplastic drugs for the treatment of lymphoid tumors.
Cerebrovascular accidents in children with cancer.
Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia.
Changes in hemopoiesis of mice of the C3H strain following transplantation of Gardner lymphosarcoma and infection with LDH-virus. III. Blood proteins.
Characterization and optimization of extracellular L-Asparaginase production by selected Actinomycete strain isolated from an algerian wheat bran.
Characterization of inhibitors acting at the synthetase site of Escherichia coli asparagine synthetase B.
Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini.
Chemical modification of L-asparaginase from Cladosporium sp. for improved activity and thermal stability.
Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma.
Childhood non-Hodgkin's lymphoma--results of treatment with ALL high-risk protocol.
Clinical pharmacology of intramuscularly administered L-asparaginase.
Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors.
Cloning and expression of L-asparaginase from Bacillus tequilensis PV9W and therapeutic efficacy of Solid Lipid Particle formulations against cancer.
Combination therapy of animal tumors with L-asparaginase and antagonists of glutamine or glutamic acid.
Comparative proteomic analysis reveals metabolic variability of probiotic Enterococcus durans during aerobic and anaerobic cultivation.
Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Comparison of glycine metabolism in mouse lymphoma cells either sensitive or resistant to L-asparaginase.
Concentrations of free amino acids and other blood components in a lymphoma patient during intensive hemodialysis.
Confinement of Therapeutic Enzymes in Selectively Permeable Polymer Vesicles by Polymerization-Induced Self-Assembly (PISA) Reduces Antibody Binding and Proteolytic Susceptibility.
Control of hypoglycemia with L-asparaginase in a patient with islet cell cancer.
Conventional-Vincristine Sulfate vs. Modified Protocol of Vincristine Sulfate and L-Asparaginase in Canine Transmissible Venereal Tumor.
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer.
Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy.
Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach.
Delayed-type hypersensitivity in response to L-asparaginase in a case of acute lymphoblastic leukemia.
Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model.
Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles.
Dietary thiamine influences l-asparaginase sensitivity in a subset of leukemia cells.
E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children.
Effect of L-asparaginase (NSC-109,229) on transplantable and spontaneous tumors from mice and rats.
Effect of vitreoscilla hemoglobin and culture conditions on production of bacterial L-asparaginase, an oncolytic enzyme.
Effect of Vitreoscilla hemoglobin on production of a chemotherapeutic enzyme, L-asparaginase, by Pseudomonas aeruginosa.
Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group.
Effects of L-asparaginase on plasma amino acid profiles and tumor burden in cats with lymphoma.
Effects of L-asparaginase on the two cases of acute leukemia with mediastinal tumors as initial signs.
Eighth new drug seminar on l-asparaginase and daunorubicin. Division of Cancer Treatment. National Cancer Institute. December 17, 1979 Bethesda, Maryland.
Elucidation of the specific function of the conserved threonine triad responsible for human L-asparaginase autocleavage and substrate hydrolysis.
Enhancement of metastases by L-asparaginase in a mouse tumor system.
Enhancement of metastases by L-asparaginase in a mouse tumour system.
Enhancement of metastases by L-asparaginase in allogeneic and isogeneic mouse tumor systems.
Enzymes as agents for the treatment of disease.
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase.
Expression of Asparagine Synthetase Predicts in vitro Response to L-asparaginase in Canine Lymphoid Cell Lines.
Expression of CD203c on basophils as a marker of immunoglobulin E-mediated l-asparaginase allergy.
Genistein enhances the effects of L-asparaginase on inducing cell apoptosis in human leukemia cancer HL-60 cells.
Genotoxic activity of L-asparaginase produced by Streptomyces ansochromogenes UFPEDA 3420.
Gliap--a novel untypical L-asparaginase localized to rat brain astrocytes.
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience.
Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.
Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties.
Immobilization of L-Asparaginase on Magnetic Nanoparticles for Cancer Treatment.
Immunity to the 6C3HED ascites tumor following treatment of tumor-bearing mice with Escherichia coli L-asparaginase.
Improving the Treatment of Acute Lymphoblastic Leukemia.
In vitro immune monitoring of antibody response in dogs given chemoimmunotherapy for lymphoma.
Influence of L-asparaginase on antibody production and growth of tumors in allogeneic mice.
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.
Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum L-asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes.
Inhibitors of L-asparagine synthetase, in vitro.
Interaction of the eucaryotic peptide chain initiation factor eIF-4A with the specific elements at the 5'-untranslated sequence of human asparagine synthetase mRNA.
Isolation and screening of extracellular anticancer enzymes from halophilic and halotolerant bacteria from different saline environments in Iran.
Kinetic studies of L-asparaginase from Penicillium digitatum.
l -asparaginase Production and Enhancement by Sarocladium strictum: In vitro Evaluation of Anti-Cancerous Properties.
L-asparaginase and PEG asparaginase--past, present, and future.
L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group.
L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors.
L-Asparaginase Exerts Neuroprotective Effects in an SH-SY5Y-A53T Model of Parkinson's Disease by Regulating Glutamine Metabolism.
L-asparaginase for the treatment of cancer.
L-asparaginase for treatment of lymphoid neoplasia in dogs.
L-asparaginase in cancer therapy.
l-asparaginase induces intrinsic mitochondrial-mediated apoptosis in human gastric adenocarcinoma cells and impedes tumor progression.
L-asparaginase produced from soil isolates of Pseudomonas aeruginosa shows potent anti-cancer activity on HeLa cells.
L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia.
L-asparaginase therapy in children with advanced leukemia. The Southwest Cancer Chemotherapy Study Group.
L-asparaginase therapy with concomitant cranial venous thrombosis: can MRI help avoiding stroke.
L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm.
L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.
L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
l-Asparaginase: a feasible therapeutic molecule for multiple diseases.
L-Asparaginase: human toxicology and single agent activity in nonleukemic neoplasms.
L-asparaginase: old dog, more tricks and leukemia: not simply a liquid tumor.
L-asparaginase: the evolution of a new tumor inhibitory agent.
L-Asparagine synthetase in serum as a marker for neoplasia.
L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.
Lipid metabolism in tumour bearing mice treated withAeromonas L-asparaginase.
Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Marine microbial L-asparaginase: Biochemistry, molecular approaches and applications in tumor therapy and in food industry.
Marine Microorganism: An Underexplored Source of l-Asparaginase.
Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
Metabolism of proteins and glycoproteins in tumour bearing mice treated with Aeromonas L-asparaginase.
Methotrexate-associated lymphoproliferative disorder presenting as extranodal NK/T-cell lymphoma arising in the lungs.
Molecular Cloning, Biochemical Characterization, and Antitumor Properties of a Novel L-Asparaginase from Synechococcus elongatus PCC6803.
Molecular dynamics simulations of human L-asparaginase1: Insights into structural determinants of enzymatic activity.
No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15.
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis.
Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
Optimization of aqueous two-phase micellar system for partial purification of L-asparaginase from Penicillium sp. grown in wheat bran as agro-industrial residue.
Optimizing the dosing schedule of l-asparaginase improves its anti-tumor activity in breast tumor-bearing mice.
Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Pancreas pseudocyst associated with L-asparaginase treatment: a case report.
Pediatric thromboembolism: a national survey in Japan.
Penetration into Cancer Cells via Clathrin-Dependent Mechanism Allows L-Asparaginase from Rhodospirillum rubrum to Inhibit Telomerase.
Perfusion trials with a collagen-immobilized enzyme in an extracorporeal reactor: activity, stability, and biocompatibility.
pH-dependent thermal stability of Vibrio cholerae L-asparaginase.
Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
Phase I evaluation of succinylated Acinetobacter glutaminase-asparaginase in adults.
Phase II study of L-asparaginase in the treatment of pancreatic carcinoma.
Polyethylene glycol acts as a mechanistic stabilizer of L-asparaginase: a computational probing.
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Potential of Anti-Cancer Activity of Secondary Metabolic Products from Marine Fungi.
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Process development for scale-up production of a therapeutic L-asparaginase by Streptomyces brollosae NEAE-115 from shake flasks to bioreactor.
Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4.
Prolonged second remissions in childhood acute lymphocytic leukemia: a report from the Childrens Cancer Study Group.
Promoter demethylation of the asparagine synthetase gene is required for ATF4-dependent adaptation to asparagine depletion.
Purification and biotechnological applications of L-asparaginase from newly isolated Bacillus halotolerans OHEM18 as antitumor and antioxidant agent.
Purification, characterization and immunogenicity assessment of glutaminase free L-asparaginase from Streptomyces brollosae NEAE-115.
Purification, characterization, cytotoxicity and anticancer activities of L-asparaginase, anti-colon cancer protein, from the newly isolated alkaliphilic Streptomyces fradiae NEAE-82.
Randomized phase II comparison of methotrexate with or without L-asparaginase in non-small cell cancer of the lung.
Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity.
Recent developments in l-asparaginase discovery and its potential as anticancer agent.
Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia.
Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.
Regeneration, tumor, dietary, and L-asparaginase effects on asparagine biosynthesis in rat liver.
Selective apoptosis of natural killer-cell tumours by l-asparaginase.
Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplantation: a first line strategy for CD4+CD56+ hematodermic neoplasm.
Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia.
Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation.
SLC1A3 contributes to L-asparaginase resistance in solid tumors.
SOX12 promotes colorectal cancer cell proliferation and metastasis by regulating asparagine synthesis.
Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells.
Studies on the recombinant production and anticancer activity of thermostable L- asparaginase I from Pyrococcus abyssi.
Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.
Surgical pancreatic complications induced by L-asparaginase.
Targeting extracellular nutrient dependencies of cancer cells.
The chemical modification of E. coli L-asparaginase by N,O-carboxymethyl chitosan.
The effects of L-asparaginase on the amino acid incorporation of mouse lymphoid tumors.
The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase.
The potential of halophilic and halotolerant bacteria for the production of antineoplastic enzymes: L-asparaginase and L-glutaminase.
The synthesis and degradation of presumptive messenger RNA in cultured mouse leukemia cells during the inhibition of protein synthesis.
Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.
Therapeutic l-asparaginase: upstream, downstream and beyond.
Therapy of a murine lymphoma with tumor-specific antiserum in combination with adriamycin, cyclophosphamide, or L-asparaginase.
Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase. Results of a Cancer and Leukemia Group B Study.
Thrombocytopenia associated with neoplasia in dogs.
TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI.
Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.
Yarrowia lipolytica L-asparaginase inhibits the growth and migration of lung (A549) and breast (MCF7) cancer cells.
[Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst]
[Antitumor activity of L-asparaginase from Erwinia carotovora from against different leukemic and solid tumours cell lines].
[Antitumor activity of L-asparaginase from Yersinia pseudotuberculosis]
[Binding of the antileukemia drug Escherichia coli L-asparaginase to the plasma membrane of normal human mononuclear cells]
[Cellular test system for studying the biological properties of preparations with L-asparaginase activity]
[Comparative pharmacokinetic study of two different ways of using L-asparaginase as the main drug in combination chemotherapy]
[Cytostatic effects of L-asparaginase on models of sensitive and resistant tumors]
[Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation]
[Experimenting with the use of L-asparaginase in the treatment of neoplasms of the blood system]
[In vitro studies using E. coli L-asparaginase on lymphatic cells of bovine leukemia and various transplantation tumors]
[Inhibition of malignant human neoplasms with L-asparaginase]
[L-asparaginase in the treatment of solid tumors and leukemia]
[L-asparaginase: A new principle in the chemotherapy of malignant neoplasms]
[Nutritional requirement of cancer cells: inhibition of the growth of cancer cells by L-asparaginase]
[Outcome of treatment protocol 8704T for childhood T cell leukemia and lymphoma]
[Results of the treatment of adult acute lymphoblastic leukemia according to ALL-2005 protocol as a basis for new trials]
[Serum L-asparaginase in tumor rats and patients of malignant tumor]
[Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia]
[Successful treatment with L-asparaginase-based combination chemotherapy for refractory T-cell post-transplant lymphoproliferative disorder]
[Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]
[The role of L-asparaginase in the chemotherapy of tumors]
[To what extent L-asparaginase affects the tumor cells? Press information of the Sektion Onkologie der Paul-Ehrlich-Gesellschaft für Chemotherapie]
Nephritis
Biochemical criteria for the evaluation of drug efficiency on adjuvant arthritis and nephrotoxic serum nephritis in the rat: studies with phenylbutazone, L-Asparaginase, colchicine, lysine acetylsalicylate, and pyridinol carbamate.
Effect of altered lymphocyte function on immunologic disorders in NZB/NZW mice.
[Use of L-asparaginase in the treatment of patients with nephritis due to lupus: immediate and midterm effects]
Nephrotic Syndrome
Pediatric thromboembolism: a national survey in Japan.
Risk factors for the development of hospital-acquired pediatric venous thromboembolism-Dealing with potentially causal and confounding risk factors using a directed acyclic graph (DAG) analysis.
[Resistance to curative treatment by unfractionned heparin.]
Neuroblastoma
Cerebrovascular accidents in children with cancer.
Neurologic Manifestations
Cerebrovascular accidents in children with cancer.
Neurotoxicity Syndromes
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia.
Neutropenia
Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma.
Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation.
Nevus
Eruptive post-chemotherapy in situ melanomas and dysplastic nevi.
Obesity
A Comprehensive Update on the Chylomicronemia Syndrome.
Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.
Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
Osteonecrosis
Avascular necrosis of bone after adult acute lymphocytic leukemia treatment with methotrexate, vincristine, L-asparaginase, and dexamethasone (MOAD).
Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy.
Osteosarcoma
Cerebrovascular accidents in children with cancer.
The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase.
Ototoxicity
[Complications of antitumor and antileukemia chemotherapy. 3 (conclusion)]
Ovarian Neoplasms
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.
L-Asparaginase Inhibits Invasive And Angiogenic Activity And Induces Autophagy In Ovarian Cancer.
Searching for pharmacogenomic markers: the synergy between omic and hypothesis-driven research.
[Cellular test system for studying the biological properties of preparations with L-asparaginase activity]
Overweight
A Comprehensive Update on the Chylomicronemia Syndrome.
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Pancreatic Pseudocyst
Delayed pancreatic pseudocyst formations. Long-term complication of L-asparaginase treatment.
Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis.
Endoscopic ultrasound-guided cystogastrostomy for successful drainage of pancreatic pseudocyst: a pediatric case report.
Pancreatic pseudocyst complicating treatment of acute lymphoblastic leukemia.
[A case of acute lymphocytic leukemia complicated with multiple pancreatic pseudocysts probably caused by L-asparaginase]
[A case of ALL complicated with acute pancreatitis and pancreatic pseudocyst caused by L-asparaginase ]
[Pancreatic pseudocyst. A case report and review of the literature]
Pancreatitis
A pilot study evaluating changes in pancreatic lipase immunoreactivity concentrations in canines treated with L-asparaginase (ASNase), vincristine, or both for lymphoma.
Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for L-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS).
Acute haemorrhagic pancreatitis following L-asparaginase therapy in acute lymphoblastic leukaemia --a case report.
Acute Pancreatitis and Diabetic Ketoacidosis following L-Asparaginase/Prednisone Therapy in Acute Lymphoblastic Leukemia.
Acute pancreatitis in association with cytosine arabinoside therapy.
Acute pancreatitis in association with L-asparaginase therapy: report of one case.
Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia After Chemotherapy.
Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia Treated With L-Asparaginase.
Adverse reactions of L-asparaginase.
An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).
Asparaginase-associated pancreatitis in children.
Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.
Asparagine Synthetase Is Highly Expressed at Baseline in the Pancreas Through Heightened PERK Signaling.
Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase.
Delayed acute pancreatitis after L-asparaginase therapy.
Delayed pancreatic pseudocyst formations. Long-term complication of L-asparaginase treatment.
Diabetes mellitus and pancreatitis as a complication of L-asparaginase therapy.
Drug-induced acute pancreatitis: further criticism.
Endoscopic ultrasound-guided cystogastrostomy for successful drainage of pancreatic pseudocyst: a pediatric case report.
Epileptic seizures after octreotide administration in a 6.5-year-old female with ALL and L-asparaginase associated pancreatitis: a possible drug interaction.
Fatal case of L-asparaginase induced pancreatitis.
Hyperglycemia induced by chemotherapeutic agents used in acute lymphoblastic leukemia: report of three cases.
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Increased serum trypsin and elastase-1 levels in patients undergoing L-asparaginase therapy.
L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia.
L-asparaginase and pancreatitis.
L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels.
L-asparaginase-induced severe acute pancreatitis in an adult with extranodal natural killer/T-cell lymphoma, nasal type: A case report and review of the literature.
L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
L-asparaginase-related pancreatic pseudocyst: report of a case.
l-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.
Latent onset of clinical pancreatitis in children receiving L-asparaginase therapy.
Minimal contribution of severe hypertriglyceridemia in L-asparaginase-associated pancreatitis developed in a child with acute lymphocytic leukemia.
Monolith and coating enzymatic microreactors of l-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
Octreotide prevents L-asparaginase-induced pancreatic injury in rats.
Pancreas pseudocyst associated with L-asparaginase treatment: a case report.
Pancreatic disorders in infancy and childhood: experience with 92 cases.
Pancreatic panniculitis caused by L-asparaginase induced acute pancreatitis in a child with acute lymphoblastic leukemia.
Pancreatic pseudocyst complicating treatment of acute lymphoblastic leukemia.
Pancreatitis in children: clinical analysis of 61 cases in southern Taiwan.
Pegaspargase-induced pancreatitis.
Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparaginase-induced pancreatitis.
Serial sonograms to detect pancreatitis in children receiving L-asparaginase.
Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia.
Severe L-asparaginase-induced Hypertriglyceridaemia Treated with Plasmapheresis.
Successful Management of a Child With Drug-induced Necrotizing Pancreatitis During Acute Lymphoblastic Leukemia Therapy: A Case Report.
Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic.
Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Surgical pancreatic complications induced by L-asparaginase.
Ureteral obstruction caused by L-asparaginase-induced pancreatitis in a child with acute lymphoblastic leukemia.
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
[A case of ALL complicated with acute pancreatitis and pancreatic pseudocyst caused by L-asparaginase ]
[Acute drug-induced pancreatitis]
[Acute pancreatitis during chemotherapy of acute lymphoblastic leukaemia complicated with pseudocyst]
[Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase]
[Acute pancreatitis secondary to L-asparaginase (a case report)]
[Delayed acute pancreatitis after treatment with L-asparaginase. A case report]
[Pancreatic pseudocyst. A case report and review of the literature]
[Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia]
[Successful readministration of L-asparaginase after development of severe hypertriglyceridemia in a young adult with T-cell acute lymphoblastic leukemia].
Pancreatitis, Acute Hemorrhagic
Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis.
Pancreatitis, Acute Necrotizing
Pancreatitis in children: clinical analysis of 61 cases in southern Taiwan.
Panniculitis
Pancreatic panniculitis caused by L-asparaginase induced acute pancreatitis in a child with acute lymphoblastic leukemia.
Paralysis
Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
Paresis
A rare complication in a child undergoing chemotherapy for acute lymphoblastic leukemia: Superior sagittal sinus thrombosis.
Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia.
[Neurologic complications during chemotherapy of children with acute lymphoid leukemia]
Parkinson Disease
L-Asparaginase Exerts Neuroprotective Effects in an SH-SY5Y-A53T Model of Parkinson's Disease by Regulating Glutamine Metabolism.
Parotitis
Acute parotitis during induction therapy including L-asparaginase in acute lymphoblastic leukemia.
Hyperglycemia and acute parotitis related to L-asparaginase therapy.
L-asparaginase induced acute parotitis during intensification therapy of acute lymphoblastic leukemia.
Phlebitis
[L-asparaginase, antithrombin III deficiency and thromboses (author's transl)]
Plasmacytoma
Antitumor effect of hippurate. An experimental study using various mouse tumor strains.
Polycythemia Vera
[L-asparaginase and L-glutaminase activities in leukocytes and plasma in polycythemia vera]
Polyneuropathies
Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
Posterior Leukoencephalopathy Syndrome
Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy.
L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.
[Reversible posterior leukoencephalopathy syndrome probably caused by L-asparaginase]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
50 Years Ago in The Journal of Pediatrics: L-Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: Optimizing Efficacy and Minimizing Toxicity.
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia.
A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography.
A critical review on properties and applications of microbial l-asparaginases.
A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.
A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
A Patent Review on the Use of L-asparaginase in the Treatment of Acute Lymphocytic Leukemia.
A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.
A potential type-II L-asparaginase from marine isolate Bacillus australimaris NJB19: Statistical optimization, in silico analysis and structural modeling.
A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
A rare complication in a child undergoing chemotherapy for acute lymphoblastic leukemia: Superior sagittal sinus thrombosis.
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase.
A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.
A trombosis story and PRES.
A Young Boy with L-asparaginase-Induced Seizure.
Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for L-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS).
Activity of bortezomib in glioblastoma.
Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
Acute leukemia in pregnancy: transient neonatal myelosuppression after combination chemotherapy in the mother.
Acute lymphoblastic leukemia in Chinese adults in Hong Kong.
Acute Pancreatitis and Diabetic Ketoacidosis following L-Asparaginase/Prednisone Therapy in Acute Lymphoblastic Leukemia.
Acute pancreatitis in association with L-asparaginase therapy: report of one case.
Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia After Chemotherapy.
Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia Treated With L-Asparaginase.
Acute parotitis during induction therapy including L-asparaginase in acute lymphoblastic leukemia.
Addition of rubidomycin to induction treatment with vincristine, prednisone, and L-asparaginase in standard-risk childhood acute lymphocytic leukemia (study ALL V): a report on behalf of the Dutch Childhood Leukemia Study Group.
Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.
Adverse reactions of L-asparaginase.
Aggressive treatment improves survival in adult acute lymphoblastic leukemia.
Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy.
Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections.
An analytical quality by design (aQbD) approach for a L-asparaginase activity method.
An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase.
An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.
Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism.
Anticoagulation treatment and prophylactic edoxaban for cerebral sinus venous thrombosis in an adolescent with acute lymphoblastic leukemia.
Antiproliferative effects of L-asparaginase in acute myeloid leukemia.
Antithrombin and fibrinogen levels as predictors for plasma L-asparaginase activity in children with acute lymphoblastic leukemia.
Antithrombin III as the Indicator of L-Asparaginase Activity in Children Treated for Acute Lymphoblastic Leukemia.
Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults.
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.
Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.
Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during BFM-based induction therapy for childhood acute lymphoblastic leukemia.
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia.
Asparagine: A Metabolite to Be Targeted in Cancers.
Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer.
Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.
Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1 driven B-cell precursor acute lymphoblastic leukemia.
Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells.
Avascular necrosis of bone after adult acute lymphocytic leukemia treatment with methotrexate, vincristine, L-asparaginase, and dexamethasone (MOAD).
Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Biophysical characterization of two commercially available preparations of the drug containing Escherichia coli L-Asparaginase 2.
Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia.
CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: a case report.
Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.
Cerebral infarction in a patient with acute lymphoblastic leukemia after fresh-frozen plasma replacement during L-asparaginase therapy.
Cerebral Thrombotic Complications Related to l-Asparaginase Treatment for Acute Lymphoblastic Leukemia: Retrospective Review of 10 Cases.
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study.
Cerebrovascular complications in cancer patients.
Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia.
Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.
Cerebrovascular complications of L-asparaginase therapy.
Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy.
Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase.
Characteristics of Blood Transfusion During Induction Remission in Children With Acute Lymphoblastic Leukemia: A Single-Center Retrospective Investigation.
Characterization of a novel asparaginase from soil metagenomic libraries generated from forest soil.
Characterization of a recombinant glutaminase-free L-asparaginase (ansA3) enzyme with high catalytic activity from Bacillus licheniformis.
Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma.
Chemical metabolic inhibitors for the treatment of blood-borne cancers.
Chemotherapy and its effect on testicular morphology in children.
Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation.
Circumventing the side effects of L-asparaginase.
Clinical characteristics of Japanese patients with severe hypertriglyceridemia.
Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia.
Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.
Coagulation abnormalities in childhood acute lymphoblastic leukemia: assessing the impact of L-asparaginase therapy in Ghana.
Coagulopathic side effect of L-asparaginase on fibrinogen level in childhood acute lymphoblastic leukemia during induction phase.
Combination chemotherapy for bone marrow relapse in childhood lymphoblastic leukaemia (ALL).
Combination chemotherapy for children with acute lymphocytic leukemia who fail to respond to standard remission-induction therapy.
Combination therapy of omega-3 fatty acids and acipimox for children with hypertriglyceridemia and acute lymphoblastic leukemia.
Comparative pharmacokinetic studies of three asparaginase preparations.
Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial.
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy.
Concomitant Use of Acyclovir and Intravenous Immunoglobulin Rescues an Immunocompromised Child With Disseminated Varicella Caused Multiple Organ Failure.
Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase.
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
Consideration of Glucocorticoids and Escherichia coli-derived L-asparaginase in the treatment of pediatric acute lymphoblastic leukemia.
Construction of expression systems for Escherichia coli asparaginase II and two-step purification of the recombinant enzyme from periplasmic extracts.
Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia.
Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer.
Curcumin potentiates antitumor activity of l-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia.
Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Delayed-type hypersensitivity in response to L-asparaginase in a case of acute lymphoblastic leukemia.
Design of starch functionalized biodegradable P(MAA-co-MMA) as carrier matrix for l-asparaginase immobilization.
Determination of L-asparaginase activity in serum by thin-layer chromatography: application to the treatment of acute lymphoblastic leukemia.
Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
Development and Validation of a Hydrophilic Interaction Liquid Chromatography Tandem Mass Spectrometry Method for the Determination of Asparagine in Human Serum.
Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles.
Development of Processes for Recombinant L-Asparaginase II Production by Escherichia coli Bl21 (De3): From Shaker to Bioreactors.
Dexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.
Diabetic ketoacidosis with L-asparaginase therapy.
Different methodologies for sustainability of optimization techniques used in submerged and solid state fermentation.
Direct long-term effects of L-asparaginase on rat and human pancreatic islets.
Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Discovery of human-like L-asparaginases with potential clinical use by directed evolution.
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.
Distinctive sensitivity of some T-leukemia cell lines to L-asparaginase.
Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study.
Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.
Early diagnosis of asparaginase-associated pancreatitis based on elevated serum elastase-1 levels: Case reports.
Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.
Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors.
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Effect of the antileukemic agent L-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells.
Effective combination treatment of advanced acute lymphocytic leukemia with cytosine arabinoside (NSC-63878) and L-asparaginase (NSC-109229).
Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group.
Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Effects of the antileukemic drug L-asparaginase on sex hormone-binding globulin: studies in vivo and in vitro.
Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis.
Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B.
Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia.
Endoscopic ultrasound-guided cystogastrostomy for successful drainage of pancreatic pseudocyst: a pediatric case report.
Enhanced catalysis of l-asparaginase from Bacillus licheniformis by a rational redesign.
Enhancement in biological activity of L-asparginase by its conjugation on silica nanoparticles.
Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.
Enzymes as agents for the treatment of disease.
Eruptive post-chemotherapy in situ melanomas and dysplastic nevi.
Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.
Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
Evaluation of the asparagine synthetase level in leukemia cells by monoclonal antibodies.
Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study.
Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Expression of a recombinant bacterial L-asparaginase in human cells.
Expression of Asparagine Synthetase Predicts in vitro Response to L-asparaginase in Canine Lymphoid Cell Lines.
Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials.
Extracellular production of the oncolytic enzyme, L-asparaginase, by newly isolated Streptomyces sp. strain NEAE-95 as potential microbial cell factories: optimization of culture conditions using response surface methodology.
Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia.
Fatal Liver Failure in an Adult Patient with Acute Lymphoblastic Leukemia following Treatment with L-Asparaginase.
Fed-Batch Production of Saccharomyces cerevisiae L-Asparaginase II by Recombinant Pichia pastoris MUT s Strain.
Fermentative production and isolation of L-asparaginase from Erwinia carotovora, EC-113.
Fibrinopeptide A changes during remission induction treatment with L-asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation.
Filamentous Fungi Producing l-Asparaginase with Low Glutaminase Activity Isolated from Brazilian Savanna Soil.
Five chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.
Gene expression of ASNS, LGMN and CTSB is elevated in a subgroup of childhood BCP-ALL with PAX5 deletion.
Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice.
Genome-wide loss-of-function genetic screening identifies opioid receptor ?1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
Genotoxic activity of L-asparaginase produced by Streptomyces ansochromogenes UFPEDA 3420.
Glucose metabolism in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules.
Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Glutaminase-free L-asparaginase production by Leucosporidium muscorum isolated from Antarctic marine-sediment.
Granulocyte-Macrophage Colony-Stimulating Factor in Newly Diagnosed Adult Patients with Acute Lymphoblastic Leukemia Treated with Conventional Chemotherapy.
Greater decrease of fibrinogen as compared to antithrombin III in L-asparaginase treated leukemia patients.
Guinea pig serum L-asparaginase: purification, and immunological relationship to liver L-asparaginase and serum L-asparaginases in other mammals.
HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.
Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules.
Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia.
High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience.
Highly efficient novel recombinant L-asparaginase with no glutaminase activity from a new halo-thermotolerant Bacillus strain.
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Histopathological features of L-asparaginase-induced liver disease.
Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo.
Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors.
Hyperglycemia, ketoacidosis and other complications of L-asparaginase in children with acute lymphoblastic leukemia.
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report.
Hypomethylation and reactivation of the asparagine synthetase gene induced by L-asparaginase and ethyl methanesulfonate.
Iatrogenic Coagulopathy and the Development of Posterior Reversible Encephalopathy Syndrome after L-asparaginase Chemotherapy.
Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome.
Identification of L-asparaginases from Streptomyces strains with competitive activity and immunogenic profiles: a bioinformatic approach.
Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL).
Immunoglobulin and granulocyte cytochemical reactions in L-asparaginase treated children with acute lymphoblastic leukemia.
Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease.
Immunological studies on modified enzymes. I. soluble L-asparaginase/mouse albumin copolymer with enzyme activity and substantial loss of immunogenicity.
Improved treatment results in the management of single and multiple relapses of acute lymphoblastic leukemia.
Improving the Treatment of Acute Lymphoblastic Leukemia.
In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
In silico modelling and molecular dynamics simulation studies on L-Asparaginase isolated from bacterial endophyte of Ocimum tenuiflorum.
In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.
Intensive therapy for adult acute lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen.
Interaction of alpha 2-macroglobulin with L-asparaginase.
Interferences that impact measuring optimal L-asparaginase activity and consequent errors interpreting these data.
Intracranial bleeding during therapy with L-asparaginase in childhood acute lymphocytic leukemia.
Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia.
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
Isolation and identification of actinomycetes for production of novel extracellular glutaminase free L-asparaginase.
Isolation and identification of L-asparaginase-producing endophytic fungi from the Asteraceae family plant species of Iran.
Kinetic studies of L-asparaginase from Penicillium digitatum.
l -asparaginase Production and Enhancement by Sarocladium strictum: In vitro Evaluation of Anti-Cancerous Properties.
L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia.
L-asparaginase and 6-diazo-5-oxo-L-norleucine synergistically inhibit the growth of glioblastoma cells.
L-asparaginase and PEG asparaginase--past, present, and future.
L-Asparaginase and Steroids-associated Hypertriglyceridemia Successfully Treated With Plasmapheresis in a Child With Acute Lymphoblastic Leukemia.
L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.
L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group.
L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors.
L-asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study.
L-asparaginase effect on antithrombin-III levels.
L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia.
L-asparaginase for treatment of childhood acute lymphoblastic leukemia: what have we learned?
L-Asparaginase from E. chrysanthemi expressed in glycoswitch®: effect of His-Tag fusion on the extracellular expression.
L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy.
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.
L-asparaginase in treatment of acute leukemia in children.
L-asparaginase induced acute parotitis during intensification therapy of acute lymphoblastic leukemia.
L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state.
L-asparaginase induced fatal cortical venous thrombosis in acute lymphoblastic leukemia.
L-asparaginase induced hypoglycemia in a case of acute lymphoblastic leukemia: a patient report.
L-asparaginase induced intracranial haemorrhage in acute lymphoblastic leukemia.
L-asparaginase induced severe hypertriglyceridemia in acute lymphoblastic leukemia with 11q23 abnormality.
L-Asparaginase induced thrombosis in acute lymphoblastic leukemia.
L-Asparaginase inhibits the rapamycin-targeted signaling pathway.
L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.
L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.
L-asparaginase Production by Leucosporidium scottii in a Bench-Scale Bioreactor With Co-production of Lipids.
l-Asparaginase Production by Moderate Halophilic Bacteria Isolated from Maharloo Salt Lake.
L-asparaginase reinduction and maintenance therapy in previously treated acute lymphocytic leukemia.
L-asparaginase related hyperglycemia.
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
L-asparaginase used with cytosine arabinoside in treatment of childhood acute lymphocytic leukemia refractory to vincristine and prednisone.
L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.
L-asparaginase--antileukemia agent.
L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha.
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.
L-asparaginase-induced apoptosis in ALL cells involves IP3 receptor signaling.
L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels.
L-asparaginase-induced Parotitis in an Elderly Patient with Acute Lymphoblastic Leukemia.
L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.
L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
L-asparaginase: a promising chemotherapeutic agent.
l-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.
L-Asparaginase: Long-Term Results of a Randomized Trial of the Effect of Additional 3 Doses During Consolidation Treatment in the Indonesian WK-ALL-2000 Protocol.
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
L-asparagine requirements of human T-lymphocytes and B-lymphocytes in culture.
L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity.
L-glutaminase and L-asparaginase by extracorporeal route in acute lymphoblastic leukemia therapy.
Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen.
Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.
Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia.
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Low Bioavailability and High Immunogenicity of a New Brand of E. colil-Asparaginase with Active Host Contaminating Proteins.
Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase.
Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS. Japan Association of Childhood Leukemia Study.
Lymphoblastic lymphoma in adults: results of a pilot protocol.
Management of hypertriglyceridemia in children with acute lymphoblastic leukemia under persistent therapy with glucocorticoids and L-asparaginase during induction chemotherapy.
Management of L-asparaginase induced prothrombotic state in acute lymphoblastic leukemia.
Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor.
Mechanism of action of L-asparaginase on the cell cycle and growth in acute lymphoblastic leukemia.
Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk?
Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.
Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase.
Microbial enzymes for deprivation of amino acid metabolism in malignant cells: biological strategy for cancer treatment.
Microbial L-asparaginase: purification, characterization and applications.
Microbial production, molecular modification, and practical application of l-Asparaginase: A review.
Minimal contribution of severe hypertriglyceridemia in L-asparaginase-associated pancreatitis developed in a child with acute lymphocytic leukemia.
Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Molecular dynamics simulations of human L-asparaginase1: Insights into structural determinants of enzymatic activity.
Monitoring of Anti-L-Asparaginase Antibody and L-Asparaginase Activity Levels in a Pediatric Patient With Acute Lymphoblastic Leukemia and Hypersensitivity to Native Escherichia coli L-Asparaginase During Desensitization Courses.
Monolith and coating enzymatic microreactors of l-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient.
Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.
Myocardial infarction in a patient with acute lymphoblastic leukemia during L-asparaginase therapy.
Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy.
Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia.
National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?
Near-haploid cell line in the blastic crisis of chronic myelogenous leukemia: a possible marker for lymphoid malignancy.
Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data.
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis.
Novel site-specific PEGylated L-asparaginase.
Octreotide prevents L-asparaginase-induced pancreatic injury in rats.
Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.
Ocular complications of sigmoid sinus thrombosis from L-asparaginase.
Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia.
Optimization of aqueous two-phase micellar system for partial purification of L-asparaginase from Penicillium sp. grown in wheat bran as agro-industrial residue.
Optimization of culture conditions and bench-scale production of anticancer enzyme L-asparaginase by submerged fermentation from Aspergillus terreus CCT 7693.
Optimization of Culture Conditions for Production of the Anti-Leukemic Glutaminase Free L-Asparaginase by Newly Isolated Streptomyces olivaceus NEAE-119 Using Response Surface Methodology.
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Pancreatic panniculitis caused by L-asparaginase induced acute pancreatitis in a child with acute lymphoblastic leukemia.
Pancreatic pseudocyst complicating treatment of acute lymphoblastic leukemia.
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study.
PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review.
PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma.
Pegaspargase.
Pegaspargase: a review of clinical studies.
Pegaspargase: an alternative?
Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020.
Perfusion trials with a collagen-immobilized enzyme in an extracorporeal reactor: activity, stability, and biocompatibility.
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study.
Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration.
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.
Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells.
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Poly (lactic-co-glycolic acid) nanospheres allow for high l-asparaginase encapsulation yield and activity.
Poly(2-vinyl-4,4-dimethylazlactone)-functionalized magnetic nanoparticles as carriers for enzyme immobilization and its application.
Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood ALL.
Population pharmacokinetics of native Escherichia coli asparaginase.
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study.
Preserving catalytic activity and enhancing biochemical stability of the therapeutic enzyme asparaginase by biocompatible multilayered polyelectrolyte microcapsules.
Production of a novel N-terminal PEGylated crisantaspase.
Production of chemotherapeutic enzyme L-asparaginase from fungal source.
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Promoter demethylation of the asparagine synthetase gene is required for ATF4-dependent adaptation to asparagine depletion.
Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.
Proteins from Erwinia asparaginase Erwinase(®) and E. coli asparaginase 2 MEDAC(®) for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia.
Purification and Characterization of Asparaginase from Phaseolus vulgaris Seeds.
Purification, Characterization and Comparison between Two New L-asparaginases from Bacillus PG03 and Bacillus PG04.
Purification, characterization and immunogenicity assessment of glutaminase free L-asparaginase from Streptomyces brollosae NEAE-115.
Purification, characterization, cytotoxicity and anticancer activities of L-asparaginase, anti-colon cancer protein, from the newly isolated alkaliphilic Streptomyces fradiae NEAE-82.
Quality-by-Design Approach for Biological API Encapsulation into Polymersomes Using "Off-the-Shelf" Materials: a Study on L-Asparaginase.
Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli.
Reduced antithrombin III levels during L-asparaginase therapy.
Relative hyperglucagonemia in L-asparaginase-and prednisone-induced glucose intolerance in management of acute lymphocytic leukemia.
Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Reversible MRI lesions due to pegaspargase treatment of non-Hodgkin's lymphoma.
Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.
Rhizobium etli asparaginase II: An alternative for acute lymphoblastic leukemia (ALL) treatment.
Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase.
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.
Salvage therapy with single agent L-asparaginase followed by local irradiation in an elderly patient with CD56-positve primary isolated extramedullary T-cell lymphoblastic lymphoma of the sinus.
Selective deficiency in collagen-induced platelet aggregation during L-asparaginase therapy.
Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL.
Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia.
Sequencing and characterization of an L-asparaginase gene from a new species of Penicillium section Citrina isolated from Cerrado.
Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine.
Sequential therapy with daunorubicin and L-asparaginase in relapses of acute lymphoblastic leukemia in children.
Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia.
Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation.
Severe hyperlipidemia in a case of acute lymphoblastic leukemia.
Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with L-asparaginase and prednisone.
SLC1A3 contributes to L-asparaginase resistance in solid tumors.
SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
Staphylococcal endocarditis presenting with a renal infarct in a patient with acute lymphoblastic leukemia.
Structural and biochemical properties of L-asparaginase.
Successful Management of a Child With Drug-induced Necrotizing Pancreatitis During Acute Lymphoblastic Leukemia Therapy: A Case Report.
Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic.
Successful management with octreotide of a child with L-asparaginase induced hemorrhagic pancreatitis.
Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child.
Successful Treatment of Adolescents and Young Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia by Novel L-Asparaginase-Intensified Induction Therapy and Cord Blood Transplantation: A Single-Center Decade Report.
Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Superior sagittal sinus thrombosis in a patient with postdural puncture headache.
Surgical pancreatic complications induced by L-asparaginase.
Symptomatic Cerebral Sinovenous Thrombosis Associated With L-Asparaginase In Children With Acute Lymphoblastic Leukemia: A Single Institution Experience Over 17 Years.
Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates.
Targeted metabolomic analysis of amino acid response to L-asparaginase in adherent cells.
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia.
The Effect of Combination of Steroid and L-Asparaginase on Hyperglycemia in Children with Acute Lymphoblastic Leukemia (ALL).
The effect of hetastarch on the stability of L-asparaginase during freeze-thaw cycling.
The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia.
The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia.
The effect of L-asparaginase on DNA and RNA synthesis by lymphoblasts of acute lymphocytic leukemia.
The effect of Yarrowia lipolytical-asparaginase on apoptosis induction and inhibition of growth in Burkitt's lymphoma Raji and acute lymphoblastic leukemia MOLT-4 cells.
The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia.
The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
The inhibition of lymphocyte blastogenesis by asparaginase: critical role of glutamine in both T and B lymphocyte transformation.
The potential of halophilic and halotolerant bacteria for the production of antineoplastic enzymes: L-asparaginase and L-glutaminase.
The prevalence and etiology of extreme hypertriglyceridemia in children: Data from a tertiary children's hospital.
The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.
Therapeutic l-asparaginase: upstream, downstream and beyond.
Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase. Results of a Cancer and Leukemia Group B Study.
Thiol-maleimide poly(ethylene glycol) crosslinking of L-asparaginase subunits at recombinant cysteine residues introduced by mutagenesis.
Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?
Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.
Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement.
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.
Thrombotic events are not exclusive to the remission induction period in patients with acute lymphoblastic leukemia: a report of two cases of cerebral sinus thrombosis.
Thrombotic Risk from Chemotherapy and Other Cancer Therapies.
Thyroid function during L-asparaginase therapy in children with acute lymphoblastic leukemia: difference between induction and late intensification.
Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Transient hyperthyroidism following L-asparaginase therapy for acute lymphoblastic leukemia.
Treatment of acute lymphoblastic leukemia in adults.
Treatment of children with advanced-stage lymphoblastic lymphoma with pegaspargase.
Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Treatment of standard-risk acute lymphoblastic leukemia in children: the results of protocol AL841 from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.
Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.
Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia.
Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Use of L-asparaginase in childhood ALL.
Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Vincristine and prednisone vs vincristine, L-asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children.
Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Yarrowia lipolytica L-asparaginase inhibits the growth and migration of lung (A549) and breast (MCF7) cancer cells.
[A case of acute lymphocytic leukemia complicated with multiple pancreatic pseudocysts probably caused by L-asparaginase]
[Acquired deficiencies in antithrombin III and C protein during treatment with L-asparaginase]
[Acquired hypofibrinogenemia in patients with leukemia during steroid therapy].
[Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase]
[Advances on the role of pegaspargase in the treatment of childhood leukemia].
[Attempt of treatment of acute lymphoblastic leukemia by L-asparaginase]
[Automated kinetic assay of plasmatic L-asparaginase activity undergoing therapy for acute lymphoblastic leukemia]
[Case of acute lymphoblastic leukemia with a striking response to L-asparaginase]
[Cerebral thrombosis in a child with acute lymphocytic leukemia during L-asparaginase therapy]
[Cerebral venous thrombosis as a complication of the treatment of acute T lymphoblastic leukemia with L-asparaginase]
[Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia]
[Comparative evaluation of the clinical effectiveness of 3 preparations of E. coli L-asparaginase]
[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]
[Complete remission obtained in refractory acute lymphocytic leukemia using high-dose cytosine arabinoside combined with low-dose L-asparaginase]
[Current national and international status of supportive therapy for the coagulopathy associated with L-asparaginase containing regimen for acute lymphoblastic leukemia].
[Desensitization therapy of acute lymphocytic leukemia with injection of L-asparaginase (Report of 5 cases)]
[Diabetic ketoacidosis and hypofibrinogenemia as a complication of the treatment with L-asparaginase of acute lymphoblastic leukemia]
[Effect of L-asparaginase on glucose metabolism in children with acute lymphoblastic leukemia]
[Further observations on the treatment of acute lymphocytic leukemia in children with L-asparaginase]
[Good response to ganciclovir in a patient of cytomegalovirus (CMV) interstitial pneumonitis and gastric ulcer following allogeneic bone marrow transplantation for acute lymphoblastic leukemia]
[Homonymous lateral hemianopsia revealing cerebral thrombophlebitis. Role of a deficiency of protein S induced by l-asparaginase]
[Hyperglycemia as a side effect of using L-asparaginase in children with acute lymphoblastic leukemia (ALL]
[Hypertriglyceridemia, Discorvered on a Pseudohyponatremia, Induced by L-asparaginase in the Treatment of B Acute Lymphoblastic Leukemia in Child].
[Hypertriglyceridemia, discovered on a pseudohyponatremia, induced by l-asparaginase in the treatment of B acute lymphoblastic leukemia in child].
[Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia]
[Intensification of induction therapy of acute lymphoblastic leukemia with L-asparaginase in children. Results of a 5-year randomised study (author's transl)]
[L-asparaginase in the therapy of acute lymphoblastic leukemia in children]
[L-asparaginase in the treatment of lymphoblastic leukemia in children]
[L-asparaginase, antithrombin III deficiency and thromboses (author's transl)]
[L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia]
[L-asparaginases of extremophilic microorganisms in biomedicine].
[Letter: Acute lymphoid leukemia: constant induction of remission by the combination of prednisone, vincristine and L-asparaginase (20 cases)]
[Lipidemic alterations in a child with acute lymphoblastic leukemia in treatment with L-aspariginase]
[New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase]
[Pancreatic pseudocyst. A case report and review of the literature]
[Preliminary observations on sequential therapy with daunorubicin and L-asparaginase in acute lymphoblastic leukemia]
[Preliminary results in the treatment of acute lymphoblastic leukemia in a child with L-asparaginase]
[Preliminary studies on the treatment of acute lymphocytic leukemia of the child with L-asparaginase]
[Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase]
[Recurrent thrombosed external hemorrhoids due to L-asparaginase administration in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient].
[Repeated treatment with L-asparaginase of acute lymphoblastic leukemia in children]
[Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia]
[Results of repeated L-asparaginase treatment in acute lymphoblastic leukemia and lymphosarcoma in children]
[Results of treatment of children with acute lymphatic leukemia (ALL) according to the ALL V protocol of the Netherlands Working Group on Leukemia in Children]
[Safety of polyethylene glycol conjugated L-asparaginase in patients with acute lymphoblastic leukemia and T cell non-Hodgkin lymphoma].
[Serial EEG-examinations in children undergoing chemotherapy of ALL according to the Berlin-West-protocol (author's transl)]
[Side effects of L-asparaginase during therapies for remission induction and maintenance in children with acute lymphocytic leukemia]
[Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia]
[Successful readministration of L-asparaginase after development of severe hypertriglyceridemia in a young adult with T-cell acute lymphoblastic leukemia].
[Superior sagittal sinus thrombosis following L-asparaginase therapy of acute lymphoblastic leukemia]
[The efficacy of using prolonged-action L-asparaginase in a treatment program for acute lymphoblastic leukemia in adults]
[The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia]
[The use of L-asparaginase in the treatment of acute lymphoblastic leukemia in childhood]
[Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia]
[Transient diabetes following treatment of acute lymphoblastic leukemia with L-asparaginase]
[Transient diabetes mellitus related to L-asparaginase therapy]
[Transient diabetes mellitus with ketoacidosis in a child during the treatment of acute lymphoblastic leukemia with L-asparaginase]
[Treatment of acute lymphoblastic leukemia in children with L-asparaginase]
[Treatment with L-asparaginase of renal and testicular involvement in acute lymphoblastic leukemia in children (author's transl)]
[Update on L-asparaginase treatment in paediatrics.]
[Use of long-acting L-asparaginase (PEG-asparaginase) in acute lymphoblastic leukemia]
[Vindesine plus L-asparaginase and prednisolone therapy (VDS-VLP therapy) for remission induction in children with relapsed acute lymphoblastic leukemia]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL.
Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.
Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature.
Vincristine could partly suppress stromal support to T-ALL blasts during pegylated arginase I treatment.
Protein Deficiency
Cerebrovascular complications of L-asparaginase therapy in children with leukemia: aphasia and other neuropsychological deficits.
Protein S Deficiency
Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.
[Homonymous lateral hemianopsia revealing cerebral thrombophlebitis. Role of a deficiency of protein S induced by l-asparaginase]
Proteinuria
Biochemical criteria for the evaluation of drug efficiency on adjuvant arthritis and nephrotoxic serum nephritis in the rat: studies with phenylbutazone, L-Asparaginase, colchicine, lysine acetylsalicylate, and pyridinol carbamate.
Effect of altered lymphocyte function on immunologic disorders in NZB/NZW mice.
Pulmonary Embolism
Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy.
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Pulmonary embolism and L-asparaginase therapy.
Quadriplegia
Coexistence of life threatening chemotherapy related leukoencephalopathy, saggital sinus thrombosis and multiple organ failure in a child with acute lymphoblastic leukemia: an unusual case with clinical recovery.
Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma.
Renal Insufficiency, Chronic
A Comprehensive Update on the Chylomicronemia Syndrome.
Sagittal Sinus Thrombosis
A rare complication in a child undergoing chemotherapy for acute lymphoblastic leukemia: Superior sagittal sinus thrombosis.
Cerebrovascular accidents in children with cancer.
Endovascular mechanical thrombectomy for superior sagittal sinus thrombosis in a patient with T-lymphoblastic lymphoma treated with L-asparaginase.
Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.
Sagittal sinus thrombosis due to L-asparaginase.
[Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]
[Superior sagittal sinus thrombosis following L-asparaginase therapy of acute lymphoblastic leukemia]
Salmonella Infections
Eugenol derivatives prospectively inhibit l-asparaginase: A heady target protein of Salmonella typhimurium.
Sarcoma
Effect of L-asparaginase from Aspergillus terreus on ascites sarcoma in the rat.
Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells.
Inhibition of Rd/3 rat sarcoma by L-asparaginase alone and in combination with sodium para-amino-salicylate.
Inhibitory activity of L-asparaginase from Mycobacterium tuberculosis on Yoshida ascites sarcoma in rats.
Studies on inhibition of viral oncogenesis. II. Inhibitory effect of L-asparaginase, clam liver extract and methotrexate on rous sarcoma virus focus formation.
The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase.
[Case of reticulum cell sarcoma treated with L-asparaginase and antibody to L-asparaginase]
[The quantative measurement of cytocidal actions of antimetabolites, Vinca alcaloids and L-asparaginase against in vitro cultured Yoshida ascites sarcoma cells]
Sarcoma 180
Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Sarcoma, Avian
Studies on inhibition of viral oncogenesis. II. Inhibitory effect of L-asparaginase, clam liver extract and methotrexate on rous sarcoma virus focus formation.
Sarcoma, Myeloid
Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to L-asparaginase.
Seizures
A rare complication in a child undergoing chemotherapy for acute lymphoblastic leukemia: Superior sagittal sinus thrombosis.
A Young Boy with L-asparaginase-Induced Seizure.
Cerebrovascular accidents in children with cancer.
Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia.
Epileptic seizures after octreotide administration in a 6.5-year-old female with ALL and L-asparaginase associated pancreatitis: a possible drug interaction.
Intracranial hemorrhage and focal seizures secondary to use of L-asparaginase during induction therapy of acute lymphocytic leukemia.
L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children.
L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
L-asparaginase-provoked seizures as singular expression of central nervous toxicity.
Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Prognosis and treatment of seizures in children with acute lymphoblastic leukemia.
Recurrent cerebrovascular accident with L-asparaginase rechallenge.
Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.
Sagittal sinus thrombosis due to L-asparaginase.
[Neurologic complications during chemotherapy of children with acute lymphoid leukemia]
Sinus Thrombosis, Intracranial
MR diagnosis of dural venous sinus thrombosis complicating L-asparaginase therapy.
Ocular complications of sigmoid sinus thrombosis from L-asparaginase.
The role of drugs in the etiology of stroke.
Spasms, Infantile
[Analysis of hypofibrinogenemias found on routine coagulation screening tests and identification of heterozygous dysfibrinogenemia or fibrinogen deficiency]
Spinal Cord Diseases
Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
Starvation
A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
Effect of l-asparaginase and asparagine deprivation on RNA metabolism in mouse leukemia L 5178Y cells in suspension culture.
EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
Heterodimers of the Arabidopsis Transcription Factors bZIP1 and bZIP53 Reprogram Amino Acid Metabolism during Low Energy Stress.
Isolation and screening of extracellular anticancer enzymes from halophilic and halotolerant bacteria from different saline environments in Iran.
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability.
Production, purification, characterization, antioxidant and antiproliferative activities of extracellular L-asparaginase produced by Fusarium equiseti AHMF4.
Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer.
The eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginase.
Utilization of D-asparagine by Saccharomyces cerevisiae.
Status Epilepticus
A rare complication in a child undergoing chemotherapy for acute lymphoblastic leukemia: Superior sagittal sinus thrombosis.
Stevens-Johnson Syndrome
L-asparaginase and toxic epidermal necrolysis.
Stomatitis
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia.
Stroke
99Tcm-HMPAO SPECT and magnetic resonance studies in L-asparaginase induced cerebrovascular accident.
Chemotherapy and cerebrovascular disease.
L-asparaginase therapy with concomitant cranial venous thrombosis: can MRI help avoiding stroke.
Neurological complications of chemotherapy to the central nervous system.
Neurosurgical management of L-asparaginase induced haemorrhagic stroke.
Recurrent cerebrovascular accident with L-asparaginase rechallenge.
Stroke due to treatment with L-asparaginase in an adult.
Strokes and the neurotoxicity of l-asparaginase.
[Stroke after treatment with L-asparaginase: correlation between clinical improvement, neuroimaging findings, and levels of coagulation factors]
Tetany
Alterations of immunoreactive somatostatin in thyroid C cells after induced hypercalcemia, hypocalcemia, and antithyroid drug treatment.
Parathyroid necrosis and hypocalcemic tetany induced in rabbits by L-asparaginase.
Thrombocytopenia
Thrombocytopenia associated with neoplasia in dogs.
Thromboembolism
Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
L-asparaginase induced fatal cortical venous thrombosis in acute lymphoblastic leukemia.
Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.
The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?
Thrombophilia
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study.
Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo.
Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report.
Pediatric thromboembolism: a national survey in Japan.
Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment.
[Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22)].
Thrombophlebitis
[Homonymous lateral hemianopsia revealing cerebral thrombophlebitis. Role of a deficiency of protein S induced by l-asparaginase]
Thrombosis
A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.
Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
Adverse effects on hemostatic function of drugs used in hematologic malignancies.
Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study.
Cerebrovascular accidents in children with cancer.
Cerebrovascular complications in cancer patients.
Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy.
Cryoprecipitate-induced mesenteric venous thrombosis during L-asparaginase therapy for acute lymphoblastic leukaemia.
Detection and treatment of central line thrombus: a case study.
Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.
Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors.
Factors with conformational effects on haemostatic serpins: implications in thrombosis.
Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children.
L-Asparaginase induced thrombosis in acute lymphoblastic leukemia.
L-asparaginase therapy with concomitant cranial venous thrombosis: can MRI help avoiding stroke.
L-asparaginase, antithrombin III, and thrombosis.
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.
Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Sagittal sinus thrombosis due to L-asparaginase.
Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia.
Symptomatic Cerebral Sinovenous Thrombosis Associated With L-Asparaginase In Children With Acute Lymphoblastic Leukemia: A Single Institution Experience Over 17 Years.
The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia.
The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.
Thromboembolic Complications in Malignant Haematological Disorders.
Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.
Thrombosis and hemorrhage during L-asparaginase therapy.
Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Thrombosis in children receiving L-asparaginase. Determining patients at risk.
Thrombosis in patients treated with L-asparaginase.
Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement.
Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia.
Thrombotic Risk from Chemotherapy and Other Cancer Therapies.
Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia.
Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
[Cerebral sinovenous thrombosis and acquired antithrombin, protein C and S deficiency during chemotherapy in a young man: report of a case]
[Cerebral sinovenous thrombosis in children due to L-asparaginase.]
[L-asparaginase, antithrombin III deficiency and thromboses (author's transl)]
Thyroid Nodule
Transient hyperthyroidism following L-asparaginase therapy for acute lymphoblastic leukemia.
Tuberculosis
Distinct functional properties of secretory l-asparaginase Rv1538c involved in phagosomal survival of Mycobacterium tuberculosis.
Identification and validation of l-asparaginase as a potential metabolic target against Mycobacterium tuberculosis.
Inhibitory activity of L-asparaginase from Mycobacterium tuberculosis on Yoshida ascites sarcoma in rats.
Rewiring of Metabolic Network in Mycobacterium tuberculosis During Adaptation to Different Stresses.
[Influence of L-asparaginase on guinea pig tuberculosis]
Tumor Lysis Syndrome
Childhood non-Hodgkin's lymphoma--results of treatment with ALL high-risk protocol.
Ureteral Obstruction
Ureteral obstruction caused by L-asparaginase-induced pancreatitis in a child with acute lymphoblastic leukemia.
Urticaria
An experience with plasma exhcange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to l-asparaginase.
Vaccinia
[Hypoparathyroidismus following L-asparaginase and vaccinia virus infection. Effect of hypocalcemia on phagocytosis and the function of lymphocytes]
[Immunity after producing vaccinia generalisata during treatment with L-asparaginase in rabbits (author's transl)]
Venereal Tumors, Veterinary
Conventional-Vincristine Sulfate vs. Modified Protocol of Vincristine Sulfate and L-Asparaginase in Canine Transmissible Venereal Tumor.
Venous Thromboembolism
L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Venous Thrombosis
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
L-asparaginase induced fatal cortical venous thrombosis in acute lymphoblastic leukemia.
L-asparaginase therapy with concomitant cranial venous thrombosis: can MRI help avoiding stroke.
Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient.
Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
Superior sagittal sinus thrombosis in a patient with postdural puncture headache.
Venous thrombosis as a complication of L-asparaginase treatment in a child.
[Cerebral venous thrombosis as a complication of the treatment of acute T lymphoblastic leukemia with L-asparaginase]
[MRI abnormalities of the brain in neurologic complications following treatment of cancer in children]
Virus Diseases
[Hypoparathyroidismus following L-asparaginase and vaccinia virus infection. Effect of hypocalcemia on phagocytosis and the function of lymphocytes]